


Cite this: *RSC Adv.*, 2022, 12, 29197

# Antimicrobial activities and mechanisms of extract and components of herbs in East Asia

Jingru Liang,  † Xuan Huang† and Guo Ma  \*

Antibacterial drugs face increasing challenges due to drug resistance and adverse reactions, which has created a pressing need for the discovery and development of novel antibacterial drugs. Herbs have played an important role in the treatment of infectious diseases. This review aims to summarize, analyze and evaluate the antibacterial activities and mechanisms of components from popular herbs in East Asia. In this review, we have searched and summarized the scientific papers published during the past twenty-year period from electronic databases such as PubMed, ScienceDirect, and Web of Science. These herbs and their components, including alkaloids, flavonoids, essential oils, terpenes, organic acids, coumarins and lignans, display potential antimicrobial effects. Herbal medicine formulas (HMFs) usually show stronger antibacterial activity than single herbs. Herbs and HMFs bring forth antibacterial activities by damaging cell membranes and walls, inhibiting nucleic acid and protein synthesis, and increasing intracellular osmotic pressure. These herbs and their components can be developed as potential and promising novel antibacterial herbal products.

Received 13th April 2022  
Accepted 3rd October 2022

DOI: 10.1039/d2ra02389j

rsc.li/rsc-advances

## Introduction

Antimicrobial drugs derived from microbial or chemical products play important roles in the fight against pathogens. However, with wide usage around the world, they have resulted in widespread drug resistance and side effects. For example, a sharp increase in the proportion and absolute number of bacteria resistant to various chemical antibacterial agents has occurred over the past decade.<sup>1</sup> Five-sixths of WHO regions have reported international drug resistance rates of 3rd gen. cephalosporins against *Escherichia coli* above 50 percent.<sup>2</sup> The increase in untreatable infections caused by the rapid emergence of multi-drug resistant and pan-drug-resistant bacteria necessitate the discovery and development of new antibacterial agents. However, the development of new antimicrobial drugs is becoming more and more difficult and costly.

Herbs have been widely used to treat bacterial infections thousands of years ago owing to multicomponent synergistic antibacterial activity. At present, 65% to 80% of people in developing countries use botanical drugs for antimicrobial treatment.<sup>3</sup> For example, about 900 years ago, the traditional Chinese medicine (TCM) *Coptis chinensis* Franch. was used to treat acute bacillary dysentery. Herb-derived products have historically been crucial in the development of antibacterial agents. Berberine extracted from *Coptis chinensis* Franch.,

*Phellodendri chinensis* C.K.Schneid. and other herbs shows significant effects against intestinal bacterial infection, and has been developed as an antibacterial agent. Tanshinone, an extract of *Salvia miltiorrhiza* Bunge, was developed into an oral drug for acne caused by *Cutibacterium acnes*. Compared with chemical antimicrobial products, herbs display less drug resistance, fewer side effects as well as reversal of antibiotic resistance when combined with antibiotics.

There have been extensive reports on antimicrobial activity, as well as the spectrum and mechanisms of action of antibacterial herbal components. The scientific papers cited in this review were extracted from the electronic databases such as PubMed, ScienceDirect, Web of Science, EBSCO OVID and Wiley Online Library. The terms used to perform the searches involved in keywords including “antimicrobial activities”, “antibacterial mechanism”, “antibacterial components”, “herbs” or “herbal medicine formulas”. “AND” or “OR” operators were used depending on the combination of terms. Through identifying and summarizing a large number of contributions already reported in the past two decades, this review illustrates pharmacodynamic substance basis and antibacterial effects of herbs in East Asia, and antibacterial mechanisms of their phytochemicals (*e.g.*, berberine, matrine, baicalein, galangin, pogostone, apigenin, oridonin, cynaroside, 3,5-di-*O*-caffeoylquinic acid, 4,5-di-*O*-caffeoylquinic acid, (+)-pinoselinol, lariciresinol, (–)-olivil-9-*O*-β-D-glucopyranoside, glochidioboside, and (+)-medioresinol) so as to provide new ideas for the discovery, development and application of antibacterial herbs.

Department of Clinical Pharmacy, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. E-mail: mg0328@fudan.edu.cn; Tel: +86-21-5198-0025

† These authors contributed equally to this article.



# Antibacterial herbs and their components

## Alkaloids

Alkaloids are commonly found in plants with complex and diverse structures. Alkaloids comprise a group of nitrogen-containing organic compounds that possess significant antimicrobial effects. Alkaloids are one of the most important active ingredients in herbs. Furthermore, they have inspired the development of several antimicrobial drugs, such as synthesis of quinine to quinolones and the structural alteration from azomycin to metronidazole.<sup>4</sup>

***Coptis chinensis* Franch.** The dried rhizome of *Coptis chinensis* Franch is often used to treat vomiting, diarrhoea, high fever and jaundice.<sup>5</sup> Berberine (Fig. 1), an isoquinoline alkaloid, is isolated from *Coptis chinensis* Franch and other herbs. Berberine is a NorA substrate that accumulates in bacterial cells, leading to DNA damage by binding both single- and double-stranded DNA.<sup>6</sup> Berberine is a substrate of multi-drug resistance (MDR) efflux pumps for Gram-negative bacteria. And MDR inhibitors can remarkably increase the antibacterial efficacy of berberine.<sup>7</sup> The activity of berberine against Gram-positive bacteria occurred primarily through the cell division protein Filamenting temperature-sensitive mutant Z (FtsZ).<sup>8</sup> Berberine hydrochloride exhibited moderate to strong activity against *S. aureus*, *E. coli*, *P. aeruginosa*<sup>9</sup> and multidrug resistant *E. coli*.<sup>10</sup> It displays antifungal effects against four pathogenic dermatophytes, *Trichophyton mentagrophytes*, *Trichophyton rubrum*, *Microsporum canis*, and *Microsporum gypseum*.<sup>11</sup> It affects the integrity of *C. albicans* cell wall, leading to mitochondrial dysfunction in fungi, which further results in increased reactive oxygen species and upregulation of oxidative stress.<sup>12</sup>

Apart from berberine, magnoflorine is also a quaternary aporphine alkaloid derived from *Coptis chinensis* Franch.

Magnoflorine exhibited an inhibitory effect against *Candida* strains with a minimum inhibitory concentration (MIC) of 50  $\mu\text{g mL}^{-1}$ .<sup>13</sup> Magnoflorine could cause damage of cell wall of *Candida albicans* by inhibiting  $\alpha$ -glucosidase activity. And it could inhibit the biofilm formation of *C. albicans*. Most toxicity studies have indicated that magnoflorine is not toxic to most cells.<sup>14</sup>

*Coptis chinensis* Franch exhibited strong antimicrobial activity, but its toxicity cannot be ignored. Some studies<sup>15</sup> indicated that the toxic constituents of *Coptis chinensis* Franch are alkaloids, e.g., berberine. The *Coptis chinensis* Franch extract rich in alkaloid was more toxic than its total extract of.<sup>15</sup> The medial lethal dose ( $\text{LD}_{50}$ ) of berberine, coptisine, palmatine and epiberberine derived from *Coptis chinensis* Franch, were determined as 713.57, 852.12, 1533.68 and 1360  $\text{mg kg}^{-1}$ , respectively. And berberine showed the highest cytotoxicity toward HepG2 and 3T3-L1 cells among the four alkaloids, while palmatine showed the lowest.<sup>16</sup>

It was reported that berberine had an inhibitory effect on human eag-related gene (hERG) channel, resulting in a long QT syndrome, which was the main cause of sudden death.<sup>17</sup> Besides, the alkaloids in *Coptis chinensis* Franch exhibited a strong inhibitory effect on acetylcholinesterase (AChE).<sup>18,19</sup> Furthermore, Berberine caused mitochondrial dysfunction, which may be associated to organ toxicity.<sup>20</sup> These studies indicates that the toxic mechanisms of alkaloids from *Coptis chinensis* Franch may be complex. And further study on toxicity of alkaloids is clearly necessary.

## Flavonoids

Flavonoids are a group of plant polyphenols commonly found in plants and are extensively used in traditional herbal medicine. Most flavonoids are structurally based on the parent compound, which has a diphenylpropane ( $\text{C}_6\text{-C}_3\text{-C}_6$ ) skeleton




Fig. 1 Chemical structure of antimicrobial herbal components.



(Fig. 1). Flavonoids display antibacterial activity primarily due to the flavonoids–membrane interaction that is related to their chemical structure, particularly the number and positions of methoxyl and hydroxyl groups.<sup>21</sup> Antimicrobial mechanism of flavonoids may include four aspects, *i.e.*, cell membrane damage,<sup>22</sup> inhibition of nucleic acid synthesis (caused by topoisomerase inhibition<sup>23</sup>), inhibition of energy metabolism (caused by NADH-cytochrome c reductase inhibition<sup>24</sup>) and inhibition of cell wall synthesis.<sup>25</sup>

***Scutellaria baicalensis* Georgi.** Baicalein (5,6,7-trihydroxyflavone, Fig. 1) is an effective bactericide isolated from *Scutellaria baicalensis* Georgi, which is widely used as an herb to treat vomiting, nausea, diarrhoea and jaundice in Asia.<sup>26</sup> Baicalein can cure bacterial infection by destroying its biofilms, inhibiting biofilm formation<sup>27</sup> and protein synthesis, influencing bacterial membrane penetrability, and inhibiting the activities of succinate dehydrogenase, malate dehydrogenase and DNA topoisomerase I and II.<sup>28</sup> Baicalein can enhance the effects of ampicillin and gentamicin against oral bacteria (fractional inhibitory concentration index, FICI < 0.375–0.5 and fractional bactericidal concentration index, FBCI < 0.5).<sup>29</sup> Baicalein also exhibits synergy with ceftazidime against *Streptococcus pyogenes*<sup>30</sup> and cefotaxime against *K. pneumoniae*.<sup>31</sup> Baicalein inhibits the activity of penicillinase to enhance the antibacterial effects of penicillins in a dose-dependent manner.<sup>32</sup> It significantly reverses the resistance of methicillin-resistant *Staphylococcus aureus* (MRSA) to ciprofloxacin by inhibiting the efflux pump of NorA *in vitro*.<sup>33</sup> It reduces the production of alpha-hemolysin and staphylococcal enterotoxin A in *S. aureus*, inhibits biofilm formation, and downregulates the quorum sensing system regulators (agrA, RNIII, and sarA in *S. aureus*) by inhibiting the transcription of quorum sensing-regulated genes and the translation of quorum sensing-signalling molecules.<sup>34</sup> For fungi, baicalin promotes apoptosis in *C. albicans* by inhibiting the activity of succinate dehydrogenase and Ca<sup>2+</sup>–Mg<sup>2+</sup> ATPase, increasing the concentration of cytoplasm Ca<sup>2+</sup> and subsequently damaging the ultrastructure.<sup>35</sup>

***Glycine max* (L.) Merr.** Soy isoflavones, which can be extracted from *Glycine max* (L.) Merr., inhibited proliferation of *L. monocytogenes* and *E. coli*.<sup>36</sup> The structure of isoflavones may be a factor in determining their antibacterial efficacy. C-5 and C-7 hydroxyl groups were very important for anti-MRSA and anti-*S. aureus* activity, and the removal or rearrangement of the prenyl group at C-6 decreased antimicrobial activity.<sup>37</sup> Dhayakaran *et al.*<sup>38</sup> found that isoflavones might alter or prevent the movement of *Listeria flagella* to impede its adherence. Soy isoflavones might also prevent nucleic acid synthesis by affecting topoisomerase I and II or by inhibiting topoisomerase IV.<sup>39</sup>

***Sophora flavescens* Aiton.** Cha *et al.*<sup>40</sup> evaluated antibacterial activities of sophora flavanone G extracted from *Sophora flavescens* Aiton against 10 clinical isolates of methicillin-resistant *S. aureus* MRSA (MICs ranged from 0.5 to 8 µg mL<sup>−1</sup>). Tsuchiya and Iinuma<sup>41</sup> suggested that sophora flavanone G exhibited antibacterial effects by reducing the fluidity of the outer and inner layers of cellular membranes. Besides, sophora flavanone B isolated from the roots of *Desmodium caudatum* (Thunb.) DC.

exhibited antimicrobial activity against MRSA (MIC, 15.6–31.25 µg mL<sup>−1</sup>).<sup>42</sup>

***Alpinia officinarum* Hance.** Galangin (Fig. 1) from *Alpinia officinarum* Hance inhibits sixteen 4-quinolone resistant *S. aureus* strains (MICs, 50 µg mL<sup>−1</sup>).<sup>43</sup> There is no cross-resistance between 4-quinolones and galangin and the antibacterial mechanism of galangin may be related to the topoisomerase IV enzyme. Galangin inhibited *S. aureus* (MIC, 32 µg mL<sup>−1</sup>)<sup>44</sup> and exhibited marked inhibitory activity against penicillinase and β-lactamase.<sup>45</sup> This inhibitory activity is due to bacterial cell membrane damage by galangin, which might occur *via* three mechanisms: inhibition of protein synthesis, effects on penicillin-binding protein 2a and interaction with penicillinase.

***Curcuma longa* L.** Curcumin (diferuloylmethane) is a natural polyphenolic flavonoid isolated from the rhizome of *Curcuma longa* L., which reduces the MICs of oxacillin, ampicillin, ciprofloxacin and norfloxacin against specific MRSA strains, and inhibits the growth of *P. aeruginosa* biofilms (MIC, 16 µg mL<sup>−1</sup>)<sup>46</sup> and 65 *H. pylori* strains *in vitro* (MICs, 5–50 µg mL<sup>−1</sup>). Curcumin is an effective therapeutic agent against *H. pylori* infection due to inhibition of NF-κB activation and *H. pylori*-induced motogenic response. Curcumin induces kinks in the filaments of *B. subtilis* and *E. coli*, indicating that it inhibits bacterial cytokinesis. In addition, formation of the FtsZ and the activity of GTPase in bacteria are strongly inhibited by curcumin.<sup>47</sup> Curcumin showed synergism with polymyxins in the treatment of bacterial infections and could ameliorated colistin-induced neurotoxicity and nephrotoxicity.<sup>48</sup>

***Pogostemon cablin* (Blanco) Benth.** *Pogostemon cablin* (Blanco) Benth. is a valuable herbal medicine that is commonly used to treat colds, fever, vomiting, nausea and diarrhoea. Pogostone (Fig. 1) from *Pogostemon cablin* (Blanco) Benth. remarkably inhibits all *C. albicans* strains (MICs, 12–97 µg mL<sup>−1</sup>; minimal fungicidal concentration (MFC), 49–97 µg mL<sup>−1</sup>)<sup>49</sup> and all fluconazole-resistant *C. albicans* strains (MICs, 3.1–50 µg mL<sup>−1</sup>).<sup>50</sup> The antimicrobial activity is associated with the length and functional group of side chains from 3' position of the pyranoid ketone ring. The functional groups, such as electron withdrawing groups, increase antibacterial activity of pogostone derivatives, while the electron donating group weakens the activity.<sup>51</sup> Furthermore, antibacterial activity vanished when the terminal side chain was linked to phenyl benzene. Oral and topical administration of pogostone significantly reduced vaginal fungal load in a vulvovaginal candidiasis mice model. The excellent antibacterial effect observed *in vivo* was due to favorable oral absorption and bioavailability of pogostone.

## Essential oils and terpenes

Most aromatic plants contain antibacterial ingredients composed of dozens of compounds, *e.g.*, alcohols, ketones, aldehydes, phenols, ethers, and lipids.<sup>52</sup> Terpenoid structures are very common in plant-derived essential oils and have been recognized to exhibit antimicrobial activities for decades. Because the antibacterial effects of essential oils are mediated by a complex coordination mechanism, the antibacterial



mechanism remains unclear. The antimicrobial effects of essential oils may be relevant to cell membrane damage caused due their composition and cytotoxic effects.<sup>53</sup> In fungal pathogens, essential oil forms membrane potential on cell wall, which destroys ATP assembly and leads to cell wall damage. Essential oil can also break down mitochondrial membrane and interfere with the electron transport system (ETS) pathway.<sup>52</sup>

***Houttuynia cordata* Thunb.** The fresh or dried aerial portion of *Houttuynia cordata* Thunb. is often used to treat lung abscess, cough and skin infections.<sup>5</sup> Methyl nonyl ketone,  $\beta$ -myrcene and bornyl acetate are the most abundant components in *Houttuynia cordata* Thunb essential oil. The essential oil from the above-ground portion of the plant exhibited strong activity against *S. aureus* (MIC,  $0.25 \mu\text{L mL}^{-1}$ ) and *Sarcina ureae* (MIC,  $0.0625 \mu\text{L mL}^{-1}$ ).<sup>54</sup> Additional essential oils from different anatomical regions and species exhibited antibacterial effects as well (MICs,  $0.0625$  to  $4.0 \mu\text{L mL}^{-1}$ ). *In vivo* experiments showed that *Houttuynia cordata* Thunb water extract was beneficial in treating murine salmonellosis infection.<sup>55</sup> Houttuynin, one of the primary active components, effectively inhibits *P. aeruginosa* biofilm dispersion.<sup>56</sup> Ultrasonically nebulized *Houttuynia cordata* Thunb can remarkably attenuate inflammation and inhibit the colonization of Gram-negative bacilli in the respiratory tract in patients after pneumonectomy.<sup>57</sup> Remarkably, *Houttuynia cordata* Thunb aerosol inhalation cures catarrhal pharyngitis.

***Agastache rugosa* (Fisch. & C.A.Mey.) Kuntze.** Essential oil extracted from the leaf of *Agastache rugosa* (Fisch. & C.A.Mey.) Kuntze exerted antibacterial effects against *E. coli* (MIC,  $9.4 \mu\text{g mL}^{-1}$ ), and essential oil from the flower inhibited *S. aureus* (MIC,  $21 \mu\text{g mL}^{-1}$ ) potentially through inhibiting biofilm activity.<sup>58</sup> Compared to penicillin, in some cases, these oils exhibited the same type of antibacterial activity, while in other cases these oils exhibited stronger activity than standard reference antibiotics (*i.e.*, penicillin, gentamycin sulfate injection).

***Cinnamomum cassia* (L.) J.Presl.** Combination of Cinnamon bark (CB) essential oil decreases MICs of piperacillin against a strain of  $\beta$ -lactamase-producing *E. coli*,<sup>59</sup> indicating that CB essential oil decreases the use of antibiotics to reduce their adverse effects, likely reversing  $\beta$ -lactam antibiotic resistance.<sup>60</sup> CB essential oil possesses antibacterial activity against Gram-negative bacteria, including *Proteus* spp. (MIC,  $1.5 \mu\text{L mL}^{-1}$ ), *K. pneumonia* (MIC,  $1.5 \mu\text{L mL}^{-1}$ ), *Yersinia enterocolitica* (MIC,  $6.25 \mu\text{L mL}^{-1}$ ) and *E. coli* (MIC,  $12.5 \mu\text{L mL}^{-1}$ ) by inhibiting biofilm formation.<sup>61</sup>

***Allium sativum* L.** *Allium sativum* L. (Garlic) extracts possess broad antibacterial spectrum and antifungal activity. Garlic essential oils were reported to exert considerable antimicrobial activity against *S. aureus*, *P. aeruginosa*, *S. epidermidis*, *Salmonella enteritidis*, *L. monocytogenes*, *Aspergillus niger*, *Penicillium cyclopium* and *Fusarium oxysporum*.<sup>62</sup> The strong antimicrobial activity exhibited by garlic essential oils is primarily related to the chemical composition of sulfides such as allicin. The disulfide bonds in these compounds contribute to the antibacterial activity. These sulfides destroy microbial cells by reacting with the sulfhydryl groups (SH) in cellular proteins to

produce disulfides.<sup>63</sup> Allicin possess broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, as well as fungi. Multiple antibiotic resistant bacterial strains, such as MRSA and other multidrug-resistant enterotoxigenic strains of *Enterococcus*, *E. coli*, *Shigella dysenteriae*, *S. flexneri*, and *S. sonnei* are sensitive to allicin.<sup>64</sup> Pure allicin exerted antifungal activity *in vitro* against *Candida*, *Cryptococcus*, *Trichophyton*, *Epidermophyton*, and *Microsporum* (MICs,  $1.57$ – $6.25 \mu\text{g mL}^{-1}$ ).<sup>65</sup> 1 mg allicin possesses antibiotic activity equivalent to that of 15 IU penicillin.<sup>66</sup> Due to the rapid reaction between thiosulfonates and thiol groups, the primary antimicrobial effect of allicin is due to inhibition of thiol-containing microbial enzymes.<sup>67</sup>

***Andrographis paniculata* (Burm.f.) Nees.** Andrographolide from the leaves of *Andrographis paniculata* (Burm.f.) Nees, exhibited broad spectrum growth inhibition activity against multiple bacteria by upregulating human  $\beta$ -defensin-2 induced through p38 MAP Kinase (MAPK) and NF- $\kappa$ B pathways in human lung epithelial cells.<sup>68</sup> Andrographolide exhibited broad spectrum growth inhibition against *E. coli*, *K. pneumonia*, *B. subtilis*, *S. aureus* (MICs,  $50$ – $100 \mu\text{g mL}^{-1}$ ), *Mycobacterium smegmatis*, *P. aeruginosa* and *Streptococcus thermophilus*.<sup>69</sup> Andrographolide increases susceptibility of *P. aeruginosa* to antibiotics (*e.g.*, cefpirome, ceftazidime and chloramphenicol) and reduces expression levels of the MexAB-OprM efflux pump.<sup>70</sup>

***Patrinia scabiosifolia* Link** *Patrinia scabiosaefolia*. Link was first recorded in the "Shennong's Herbal Classic of Materia Medica." It is commonly used to treat appendicitis, carbuncle sores and lung abscesses. This medicinal herb inhibits proliferation in AmpC  $\beta$ -lactamase-producing bacteria.<sup>71</sup> Oleanolic acid plays an important role in the antimicrobial actions of the herb, which has been illustrated against many human bacterial pathogens, *e.g.*, *S. pneumonia* (MIC,  $16 \mu\text{g mL}^{-1}$ ), methicillin-sensitive *Staphylococcus aureus* (MSSA) (MIC,  $8 \mu\text{g mL}^{-1}$ ), MRSA (MIC,  $64 \mu\text{g mL}^{-1}$ ), *B. subtilis* (MIC,  $8 \mu\text{g mL}^{-1}$ ), *Enterococcus faecalis* (MIC,  $6.25$ – $8.00 \mu\text{g mL}^{-1}$ ) and *E. faecium* (MIC,  $8 \mu\text{g mL}^{-1}$ ).<sup>72</sup> The antimicrobial abilities of oleanolic acid are mediated by affecting efflux pumps and inducing stress responses. Grudniak *et al.*<sup>73</sup> found that treatment of *E. coli* with oleanolic acid altered the synthesis of DnaK, which induced a heat-shock response. Kurek *et al.* verified that oleanolic acid affects the bacterial cell wall by inhibiting peptidoglycan turnover in *L. monocytogenes*.<sup>74</sup>

***Rabdosia rubescens* (Hemsl.) H.Hara.** *Rabdosia rubescens* (Hemsl.) H.Hara. has been used as a tea drink for more than 1100 years. The antibacterial effects of ethanol extracts from the herb against *S. aureus* may occur through disruption of the cell wall and leakage of cellular contents. Oridonin, a bioactive ent-kaurane diterpenoid, is one of the primary antibacterial active ingredients in *Rabdosia rubescens* (Hemsl.) H.Hara. and exhibits antibacterial activity against *S. aureus*, MRSA,  $\beta$ -lactamase-producing *S. aureus* (MIC is  $3.125$ ,  $6.25$ , and  $6.25 \mu\text{g per disc}$ , respectively)<sup>75</sup> and *Mycobacterium phlei* (MIC,  $16 \mu\text{g mL}^{-1}$ ).<sup>76</sup> The antimycobacterial activity of oridonin might be significantly increased by introduction of a *trans*-cinnamic moiety. The C-1 substituents of oridonin may affect its antibacterial activity.





***Thymus mongolicus* (Ronniger) Ronniger.** Thymol is the primary monoterpene phenol in essential oils isolated from Lamiaceae family plants (e.g., *Thymus mongolicus* (Ronniger) Ronniger and other plants). Thymol possesses antimicrobial activity against Gram-positive bacteria (e.g., *S. aureus*, *S. epidermidis*, *B. cereus*) and Gram-negative bacteria (e.g., *E. coli*, *P. aeruginosa*, *Enterococcus faecalis*, *Vibrio parahaemolyticus*, *Vibrio alginolyticus* and *Salmonella typhimurium*) with MICs of 32–64  $\mu\text{g mL}^{-1}$ .<sup>77</sup> Furthermore, thymol possesses concentration-dependent inhibitory activity against ethidium bromide cell efflux. In addition, thymol exerts significant anti-biofilm activity.<sup>78</sup>

***Salvia miltiorrhiza* Bunge.** Cryptotanshinone and dihydrotanshinone I from *Salvia miltiorrhiza* Bunge showed broad antibacterial activity against a wide spectrum of Gram-positive bacteria<sup>79</sup> by inhibiting the action of topoisomerase I and generating superoxide radicals in *B. subtilis* lysates, which non-selectively inhibit DNA, RNA, and protein synthesis. Cryptotanshinone and dihydrotanshinone I inhibit *A. tumefaciens*, *E. coli*, *P. lachrymans*, *R. solanacearum*, *X. vesicatoria*, *B. subtilis*, *S. aureus*, *S. haemolyticus* and *M. oryzae* (MICs, 6.25  $\mu\text{g mL}^{-1}$  to 100  $\mu\text{g mL}^{-1}$ ).<sup>80</sup> Tanshinone from *Salvia miltiorrhiza* Bunge is safe and effective against acne. Neither resistance nor obvious side effects were observed in the clinical trial.<sup>81</sup>

***Apium graveolens* L.** Sedanolide from *Apium graveolens* L. seeds inhibits *Candida parapsilosis* and *C. albicans*.<sup>51</sup> *Apium graveolens* L. essential oils, consisting of indenolide, neo-sebactam and phytadiene, exhibited antifungal activity against *Candida albicans*, *Candida tropicalis*, *Candida krusei*, *Candida guilliermondii*, *Candida parapsilosis*, *Cryptococcus neoformans*, *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *T. mentagrophytes* var. *interdigitale*, *Trichophyton verrucosum*, *Microsporum canis*, *Microsporum gypseum*, *Epidermophyton floccosum*, *Aspergillus niger*, *Aspergillus fumigatus* and *Aspergillus flavus* (MICs, 0.04–0.64  $\mu\text{L mL}^{-1}$ ).<sup>82</sup> Apigenin is a flavonoid that is abundant in *A. graveolens*; the MICs of apigenin against Gram-positive and Gram-negative strains ranged from 32.5 to 62.5  $\mu\text{g mL}^{-1}$ . Apigenin significantly reduces the MIC of ampicillin (from 800  $\mu\text{g mL}^{-1}$  to 107  $\mu\text{g mL}^{-1}$ ), and ceftriaxone (from 58  $\mu\text{g mL}^{-1}$  to 2.6  $\mu\text{g mL}^{-1}$ ) against MRSA.<sup>83</sup> Apigenin inhibited DNA gyrase, leading to the quinolone resistance mutation *gyrA* (Ser84Leu).<sup>84</sup> Liu *et al.*

### Organic acids

The antibacterial activity of organic acids may depend upon the physiological characteristics of the organism and the physico-chemical status of the external environment.<sup>85</sup> The bacteriostasis of organic acids is species specific because not all bacteria are affected by organic acids in a similar manner. Bacteria that cannot decrease their intracellular pH accumulate organic acid anions according to their pH gradient across the cell membrane.<sup>86</sup> The bacteriostatic action of organic acids involves the following five possible mechanisms: energy competition between active transport of hydrogen ions and normal metabolism of bacteria, inhibition of bacterial cell membrane stability, increased intracellular osmotic pressure, inhibition of

biomacromolecule synthesis and induction of antimicrobial peptides in host cells.<sup>87</sup>

***Lonicera japonica* Thunb.** *Lonicera japonica* Thunb. (Honey-suckle flower) is the dried flower bud or opening flower of *Lonicera japonica* Thunb. Cynaroside, 3,5-di-O-caffeoylquinic acid and 4,5-di-O-caffeoylquinic acid from *Lonicera japonica* leaves possessed the strongest antimicrobial activities against *S. aureus* and *E. coli*.<sup>88</sup> Chlorogenic acid inhibits proliferation of *S. aureus* and disrupts cell membrane permeability.<sup>89</sup> Oleanolic acid displayed antimicrobial effects against *Mycobacterium tuberculosis* (MIC, 25  $\mu\text{g mL}^{-1}$ ), *M. tuberculosis*, streptomycin-, isoniazid-, rifampin-, and ethambutol-resistant strains (MIC, 50  $\mu\text{g mL}^{-1}$ ).<sup>90</sup> In addition, ursolic acid eliminates *M. tuberculosis* at 100  $\mu\text{g mL}^{-1}$ , while inhibiting *S. mutans* and *S. sobrinus*.<sup>91</sup> These antibacterial actions are due to disruption of bacterial membrane integrity, as well as inhibition of protein synthesis and metabolic pathways.<sup>92</sup> Oleanolic acid and ursolic acid affect multiple genes involved in *S. mutans* metabolism to inhibit glycolysis, as well as synthesis of amino acids, fatty acids and peptidoglycans, all of which contribute to its antimicrobial activity.<sup>90</sup>

***Glycyrrhiza glabra* L.** Glycyrrhizic acid from *Glycyrrhiza glabra* L. enhanced the antibacterial effects of gentamicin against intrinsically resistant *Enterococcus faecium*.<sup>93</sup> Glycyrrhizic acid at a subinhibitory concentration of 2.4 mM decreased the MIC of gentamicin in intrinsically resistant *E. faecium* strains to 6.25%, and low concentrations of glycyrrhizic acid (18  $\mu\text{M}$ ) increased the susceptibility of some *E. faecium* to gentamicin. 18 $\beta$ -glycyrrhetic acid isolated from the root of the herb displays bactericidal activity against MRSA at high concentrations, reducing virulence gene expression in *S. aureus* at sublethal doses.<sup>94</sup>

***Portulaca oleracea* L.** *Portulaca oleracea* L. is the dry aerial portion of the plant and is one of the most widely used medicinal plants according to WHO. *Portulaca oleracea* L. exhibits antimicrobial activity against *N. gonorrhoea*, *S. aureus*, *E. coli* and *B. subtilis*.<sup>95</sup> Two active ingredients, linoleic and oleic acids isolated from the herb, exhibit antibacterial activity against MRSA when combined with erythromycin.<sup>96</sup> The mechanism of their antimicrobial activity is potentially due to inhibition of bacterial cell efflux pumps.<sup>97</sup>

***Rheum palmatum* L.** *Rheum palmatum* L. extracts inhibit Gram-negative and -positive bacterial strains.<sup>98</sup> The major active components include five hydroxyanthraquinones, namely, rhein, aloe-emodin, emodin, chrysophanol and physcion.<sup>99</sup> Rhein possesses the greatest antibacterial activity against *Helicobacter pylori* (MIC, 50  $\mu\text{g mL}^{-1}$ ) and *Porphyromonas gingivalis* (MIC, 2.5  $\mu\text{g mL}^{-1}$ ), and rhein decreases the expression of vital virulence factor genes in *P. gingivalis*.<sup>100</sup> Rhein also significantly increases the antibacterial activity of amoxicillin against *H. pylori*. Rhein increase cell permeability of *E. coli* and *Salmonella*, causing leakage of cell contents and eventually leading to bacterial cell death.<sup>101</sup>

### Polysaccharides

Polysaccharides are carbohydrate polymers in which at least 10 monosaccharides are linked by glycosidic bonds. In particular,

oligosaccharides derived from *Cordyceps sinensis* (BerK.) Sacc., *Astragalus mongholicus* Bunge, *Taraxacum mongolicum* Hand.-Mazz. and *Rosa laevigata* Michx. have attracted considerable attention in recent years. Despite accumulating research on polysaccharides from herbs and mounting evidence suggesting that polysaccharides possess significant pharmacological effects, the underlying molecular mechanisms of polysaccharide antibacterial properties remain ill-defined.<sup>102</sup>

**Cordyceps cicadae.** Polysaccharides from *Cordyceps cicadae* (*C. cicadae*) display broad spectrum activity against *E. coli*, *Klebsiella pneumonia*, *Vibrio cholera*, *P. aeruginosa*, *Vibrio alginolyticus*, *S. aureus*, *Vibrio parahaemolyticus* and *Streptococcus pneumonia*, demonstrating maximum activity against *V. parahaemolyticus*.<sup>103</sup> Zhang *et al.*<sup>104</sup> extracted a water-soluble polysaccharide from *C. cicadae*, demonstrating that it exhibited antibacterial activity against *E. coli*, *S. aureus*, *B. subtilis*, *Salmonella paratyphi* and *P. aeruginosa*. *C. cicadae* polysaccharides exert their bactericidal effects through destruction of the bacterial cell wall and membrane, increasing cell permeability and resulting in structural lesions and release of cellular components.

**Rosa laevigata Michx.** Crude ethanol extracts from *Rosa laevigata* Michx. exhibited anti-MRSA activity.<sup>105</sup> Polysaccharides extracted from the herb exhibit significant inhibitory effects against *E. coli*, *Paratyphoid bacillus* and *S. aureus*.<sup>106</sup> At concentrations of 10–15 mg mL<sup>-1</sup>, the inhibitory effects of polysaccharide against *S. aureus*, *P. bacillus* and *Saccharomyces cerevisiae* were stronger than that of streptomycin (50 ppm).

## Coumarins

Coumarin compounds that contain 1,2-benzopyrone structures are considered potential antibacterial agents due to their structural similarity to quinolone. They display excellent inhibitory activity against MRSA and methicillin-resistant *Staphylococcus epidermidis* (MRSE), arousing significant interest in the field of pharmacology. Some natural coumarin compounds, such as novobiocin, chlorobiocin and coumermycin A1, have been used as a new type of antibiotic to treat infections caused by Gram-positive bacteria. Other natural coumarin compounds are waiting to be developed, such as decursinol angelate and decursin, isolated from *Angelica gigas* Nakai exhibit significant activity against *B. subtilis* with MICs of 50 µg mL<sup>-1</sup> and 12 µg mL<sup>-1</sup>, respectively.<sup>107</sup>

**Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav.** 5-Methoxy-8-hydroxypsoresalen isolated from the medicinal herb is lethal to *Streptococcus iniae*.<sup>108</sup> Imperatorin, another coumarin extracted from the herb, possesses clear antibacterial activity. Imperatorin significantly inhibits the production of alpha-hemolysin (Hla) in *S. aureus* by reducing transcriptional levels of the gene encoding Hla and its accessory gene regulator. Furthermore, imperatorin prevented A549 epithelial cell injury induced by Hla in a co-culture system.<sup>109</sup>

**Fraxini Cortex.** *Fraxini Cortex* is a commonly used herbal medicine that was first recorded in the Shennong's Herbal Classic of Materia Medica. It is composed of dry branch or bark material from *Fraxinus rhynchophylla* Hance, *Fraxinus chinensis*

Roxb., *Fraxinus szaboana* Lingelsh. and *Fraxinus stylosa* Lingelsh. *Fraxini Cortex* is used to treat enteritis, excessive leucorrhoea, chronic bronchitis, bacterial dysentery and other disorders.<sup>5</sup> Liu *et al.*<sup>110</sup> found that five coumarin monomers from *Fraxinus cortex* extracts displayed significant inhibitory and bactericidal effects against *E. coli*, *S. aureus*, and *P. aeruginosa*. The antibacterial activity of those five coumarins from strongest to weakest is fraxetin, aesculetin, aesculin, fraxin and 6,7-dichomethoxyl-8-hydroxycoumarin. Coumarins, such as aesculin, significantly inhibit the growth of *E. coli* in animal organs.<sup>111</sup> Fraxetin displayed antibacterial activity against *E. coli* (MIC, 40 µg mL<sup>-1</sup>). The mechanism whereby this occurs might be due to altered permeability of the bacterial cell membrane, inhibition of bacterial soluble protein synthesis and elimination of bacterial plasmids.<sup>112</sup> Fraxetin inhibits the activity of *S. aureus* by increasing cell membrane permeability, inhibiting bacterial DNA and RNA synthesis, and decreasing topoisomerase I and II the activity.<sup>113</sup>

## Lignans

Lignans are a class of secondary plant metabolite that are produced by the oxidative dimerization of two phenylpropanoid units. Although the molecular skeleton of lignans is only comprised of two phenylpropane (C6–C3) units, lignans exhibit enormous structural diversity.<sup>114</sup> However, current research on the antimicrobial constituents of lignans is still very limited. Lignans, *e.g.*, forsythin and forsythoside, were found in *Forsythia suspensa* (Thunb.) Vahl as possible antibacterial agents.

**Schisandra chinensis (Turcz.) Baill.** *Schisandra chinensis* extract displays inhibitory effects against *E. coli*, *B. subtilis*, *Salmonella* and *S. aureus*<sup>115</sup> as well as ciprofloxacin-resistant *E. coli*. The primary antibacterial components of the plant are lignans, namely, schisandrin and schisandrin A. Possible antibacterial effects include destruction of the smooth morphology of the bacterial cell membrane, causing leakage of contents and resulting in metabolic disorders that affect the absorption of carbohydrates and other nutrients.<sup>116</sup>

**Sambucus williamsii Hance.** Pinoresinol, lariciresinol, (–)-olivil-9'-O-β-D-glucopyranoside, glochidioboside and (+)-medioresinol isolated from *Sambucus williamsii* Hance exhibit antifungal effects. Compared to amphotericin B, (–)-olivil-9'-O-β-D-glucopyranoside exhibited favorable antifungal activity against *C. albicans* by destroying the cell membrane.<sup>117</sup> (+)-Pinoresinol, lariciresinol and glochidioboside, also display antifungal effects by damaging the fungal plasma membrane without haemolysis.<sup>118</sup> (+)-Medioresinol affects mitochondria and induces reactive oxygen species accumulation in *C. albicans* cells. Reactive oxygen species induce oxidative stress and increase mitochondrial dysfunction, leading to the release of pro-apoptotic factors.

**Magnolia officinalis Rehder & E.H.Wilson.** *Magnolia officinalis* extract (MOE) is rich in lignans, among which magnolol and honokiol are the two major constituents with potent antimicrobial activity against *Listeria monocytogenes*, *Streptococcus faecalis*, *Escherichia coli*, *Salmonella*, *typhimurium*, *S. aureus*,



Table 1 Herbal medicine formulas with antimicrobial activity described during the past twenty-year period<sup>a</sup>

HMF	Formula composition	Antimicrobial spectrum	Ref.
Gegen Qinlian oral liquid	<i>Puerariae Radix</i> , <i>Scutellaria baicalensis</i> Georgi, <i>Coptis chinensis</i> Franch.	<i>Enterococcus</i> (MIC: 20.83 µg mL <sup>-1</sup> ), <i>Salmonella</i> (MIC: 41.7 µg mL <sup>-1</sup> ), <i>Escherichia coli</i> (MIC: 62.5 µg mL <sup>-1</sup> )	127
Pudilan oral liquid	<i>Taraxacum mongolicum</i> Hand.-Mazz., <i>Scutellaria baicalensis</i> Georgi, <i>Isatis tinctoria</i> L., <i>Corydalis bungeana</i> Turcz.	<i>Staphylococcus aureus</i> , <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> , <i>C. albicans</i>	128
Sanhuang tablets	<i>Rheum palmatum</i> L., <i>Scutellaria baicalensis</i> Georgi, <i>Coptis chinensis</i> Franch.	Hemolytic <i>Streptococcus B</i> , <i>Staphylococcus aureus</i> , <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> , <i>Bacillus subtilis</i> , <i>Candida albicans</i>	
Qingkailing injection	Cholic acid, mother of pearl, swine deoxycholic acid, baicali, <i>Gardenia jasminoides</i> J.Ellis, <i>Cornus officinalis</i> Siebold & Zucc., <i>Isatis tinctoria</i> L., <i>Lonicera japonica</i> Thunb.	ESBLs-producing <i>Klebsiella pneumonia</i>	129
Shuanghuanglian powder-injection	<i>Lonicera japonica</i> Thunb., <i>Forsythia suspensa</i> (Thunb.) Vahl, <i>Scutellaria baicalensis</i> Georgi	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i> , ESBLs-producing <i>Klebsiella pneumonia</i> extensively drug resistant <i>Acinetobacter baumannii</i> , pan-resistant <i>Klebsiella pneumoniae</i>	130
		ESBLs-producing <i>Klebsiella pneumonia</i> , MRSA	131
Coptis chinensis injection	<i>Phellodendri Chinensis</i> C.K.Schneid., <i>Coptis chinensis</i> Franch., <i>Scutellaria baicalensis</i> Georgi, <i>Gardenia jasminoides</i> J.Ellis	ESBLs-producing <i>Klebsiella pneumonia</i> , MRSA	132
Musk-Coptis injection	<i>Phellodendri Chinensis</i> C.K.Schneid., <i>Coptis chinensis</i> Franch., <i>Scutellaria baicalensis</i> Georgi, <i>Gardenia jasminoides</i> J.Ellis	ESBLs-producing <i>Klebsiella pneumonia</i> , MRSA	
Zhili powder	<i>Scutellaria baicalensis</i> Georgi, <i>Isatis tinctoria</i> L., <i>Taraxacum mongolicum</i> Hand.-Mazz., <i>Forsythia suspensa</i> (Thunb.) Vahl	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Salmonella</i>	133
Forsythia powder	<i>Forsythia suspensa</i> (Thunb.) Vahl, <i>Lonicera japonica</i> Thunb., <i>Platycodon grandiflorus</i> (Jacq.) A.DC., <i>Mentha canadensis</i> L., <i>Lophatherum gracile</i> Brongn., <i>Glycyrrhiza uralensis</i> Fisch., <i>Nepeta cataria</i> L., <i>Sojae Semen Praeparatum</i> , <i>Arctium lappa</i> L.	MRSA, MSSA	134
Jinhuang power	<i>Aucklandia lappa</i> DC., <i>Coptis chinensis</i> Franch., <i>Scutellaria baicalensis</i> Georgi, <i>Phellodendri Chinensis</i> C.K.Schneid., <i>Rheum palmatum</i> L., <i>Curcuma longa</i> L., <i>Angelica dahurica</i> (Hoffm.) Benth. & Hook.f. ex Franch. & Sav., <i>Trichosanthes kirilowii</i> Maxim., <i>Magnolia officinalis</i> Rehder & E.H.Wilson, <i>Citrus reticulata</i> Blanco, <i>Atractylodes lancea</i> (Thunb.) DC., <i>Arisaema heterophyllum</i> Blume, <i>Pinellia ternata</i> (Thunb.) Makino, <i>Glycyrrhiza</i> , <i>Bletilla striata</i> (Thunb.) Rehb.f.	MRSA ATCC 43300, <i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Pseudomonas maltophilia</i>	135
Ramuli Cinnamomi Decoction	<i>Arctium lappa</i> L., <i>Paeonia lactiflora</i> Pall., <i>Glycyrrhiza uralensis</i> Fisch., <i>Zingiber officinale</i> Roscoe, <i>Ziziphus jujuba</i> Mill.	MRSA, MSSA	



Table 1 (Contd.)

HMF	Formula composition	Antimicrobial spectrum	Ref.
Xiao Chaihu Decoction	<i>Bupleurum scorzonerifolium</i> Willd., <i>Pinellia ternata</i> (Thunb.) Makino, <i>Glycyrrhiza uralensis</i> Fisch., <i>Scutellaria baicalensis</i> Georgi, <i>Zingiber officinale</i> Roscoe, <i>Ziziphus jujuba</i> Mill.	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i>	136
Modified Xiaochaihutang	<i>Bupleurum scorzonerifolium</i> Willd., <i>Codonopsis pilosula</i> (Franch.) Nannf., <i>Coptis chinensis</i> Franch., <i>Zingiber officinale</i> Roscoe, <i>Poria</i> , <i>Atractylodes macrocephala</i> Koidz.	<i>H. pylori</i>	137
Pulsatillae Decoction	<i>Pulsatilla chinensis</i> (Bunge) Regel, <i>Coptis chinensis</i> Franch., <i>Phellodendri Chinensis</i> C.K.Schneid., <i>Fraxini Cortex</i>	<i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Shigella flexneri</i> , <i>Shigella sonnei</i>	
Formulas 1	<i>Astragalus mongholicus</i> Bunge, <i>Salvia miltiorrhiza</i> Bunge, <i>Forsythia suspensa</i> (Thunb.) Vahl, <i>Carthamus tinctorius</i> L.	<i>Staphylococcus aureus</i> , <i>Streptococcus agalactiae</i>	138
Formulas 2	<i>Coptis chinensis</i> Franch., <i>Salvia miltiorrhiza</i> Bunge, <i>Forsythia suspensa</i> (Thunb.) Vahl, <i>Carthamus tinctorius</i> L.	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus agalactiae</i>	
Formulas 3	<i>Astragalus mongholicus</i> Bunge, <i>Salvia miltiorrhiza</i> Bunge, <i>Coptis chinensis</i> Franch., <i>Carthamus tinctorius</i> L.	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus agalactiae</i>	
Formulas 4	<i>Scutellaria baicalensis</i> Georgi, <i>Isatis tinctoria</i> L., <i>Taraxacum mongolicum</i> Hand.-Mazz., <i>Forsythia suspensa</i> (Thunb.) Vahl	<i>Escherichia coli</i> , <i>Staphylococcus aureus</i> , <i>Salmonella</i>	139

<sup>a</sup> HMF: herbal medicine formulas. MIC: minimal inhibit concentration. ESBLs: extended spectrum beta-lactamases. MRSA: methicillin-resistant *Staphylococcus aureus*. MSSA: methicillin-sensitive *Staphylococcus aureus*.

*Bacillus anthracis*, *A. actinomycetemcomitans*, *S. mutans*, and MRSA.<sup>119,120</sup> Also, magnolol and honokiol in MOE, which is recently applied for the treatment of human oral diseases, exhibit strong inhibitory effect on oral pathogens such as periodontitis and cariogenic bacteria as well as a relatively low cytotoxic effect against human gingival fibroblasts and epithelial cells.<sup>121,122</sup> MIC of honokiol was 10  $\mu\text{g mL}^{-1}$  for *A. actinomycetemcomitans*, *S. mutans*, *S. aureus* and MRSA. Except *S. aureus* (MIC, 20  $\mu\text{g mL}^{-1}$ ), MIC of magnolol was also 10  $\mu\text{g mL}^{-1}$  for the microbes mentioned above.<sup>119</sup> On top of that, both constituents exhibit stable antimicrobial effect over a wide range of temperatures and pH against the above microbes. Magnolol and honokiol bring forth antimicrobial activity by damaging microbial cell walls or membranes, resulting in increased permeability of cell membrane, which leads to the loss of intracellular components and inhibitory effect on microbial growth.<sup>123</sup> Besides, magnolol and honokiol could also interact with cell membrane enzymes and proteins, leading to the impairment of cell structure and changes in cell morphology. Moreover, magnolol and honokiol inhibit the expression of drug-resistance *mec* gene, which is conducive to reducing the drug-resistance property of MRSA.<sup>119</sup>

## Herbal medicine formulas

The effective ingredients in herbal medicine formulas (HMF) are the material basis for their therapeutic effect. Gegen Qinlian oral liquid exhibit significant antibacterial effects on *Enterococcus* (MIC, 20.83  $\mu\text{g mL}^{-1}$ ), *Salmonella* (MIC, 41.7  $\mu\text{g mL}^{-1}$ ), and *Escherichia coli* (MIC, 62.5  $\mu\text{g mL}^{-1}$ ),<sup>124</sup> which is stronger than that of single *Pueraria lobata* (Willd.) Ohwi, *Scutellaria baicalensis* Georgi and *Coptis chinensis* Franch extract. The Chinese compound gallnut (*Rhus chinensis* Mill., *Rheum palmatum* L., *Scutellaria baicalensis* Georgi) shows antimicrobial activity against *Aeromonas sobria*, *Aeromonas caviae*, *Edwardsiella tarda*, and *Flavobacterium columnare*. And the effectively antimicrobial compounds of this formula are gallic acid, baicalin and quercetin, among which gallic acid accounts for the highest percentage of 10.47% and quercetin shows moderately antimicrobial activity with a MIC range of 125–312.5  $\mu\text{g mL}^{-1}$ .<sup>125</sup> A mixture of *Scutellaria baicalensis*, *Fraxini Cortex*, *Pulsatilla chinensis* (Bunge) Regel and *Sophora flavescens* Aiton (mixed at a ratio of 1 : 4 : 1 : 2) showed greater antibacterial activity against *S. aureus*, *E. Coli* and *Salmonella*.<sup>126</sup> It is also noted that the MIC values for HMF (usually >100  $\mu\text{g mL}^{-1}$ ) are always





Table 2 Herbal extracts and compounds with antimicrobial activity described during the past twenty-year period<sup>a</sup>

Herbal medicine	Extract/compound	Bacteria	Antimicrobial activity (MIC)	Ref.
<b>Alkaloids</b>				
<i>Coptis chinensis</i> Franch.	Berberine hydrochloride	<i>Candida albicans</i>	160 µg mL <sup>-1</sup>	143
		ETEC	1.75 to 1.96 µM	10,12
	Berberine	<i>Trichophyton mentagrophytes</i>	250.4 µg mL <sup>-1</sup>	
		<i>Trichophyton rubrum</i>	125 µg mL <sup>-1</sup>	
		<i>Microsporum canis</i>	62 µg mL <sup>-1</sup>	
		<i>Microsporum gypseum</i>	125 µg mL <sup>-1</sup>	
<i>Sophora flavescens</i> aiton	Alkaloid extract	<i>P. aeruginosa</i>	62.5 µg mL <sup>-1</sup>	144
<i>Delphinium cashmerianum</i> Royle	Ethyl acetate extract	<i>B. subtilis</i>	62.5 µg mL <sup>-1</sup>	
		<i>S. pneumonia</i>	6.25 µg mL <sup>-1</sup>	145
		<i>K. pneumoniae</i>	25 µg mL <sup>-1</sup>	
	Methanol extracts	<i>C. albicans</i>	50 µg mL <sup>-1</sup>	
		<i>S. pneumonia</i>	25 µg mL <sup>-1</sup>	
<b>Flavonoids</b>	<i>Curcuma longa</i> L.	<i>N. mucosa</i>	50 µg mL <sup>-1</sup>	
		MRSA	125–250 µg mL	42,146
	Aqueous extract	<i>S. epidermis</i> ATCC 12228	4 × 10 <sup>3</sup> µg mL <sup>-1</sup>	147
		<i>S. aureus</i> ATCC 25923	6 × 10 <sup>3</sup> µg mL <sup>-1</sup>	
		<i>K. pneumoniae</i> ATCC 10031	1.6 × 10 <sup>4</sup> µg mL <sup>-1</sup>	
		<i>E. coli</i> ATCC 25922	4 × 10 <sup>3</sup> µg mL <sup>-1</sup>	
	<i>Scutellaria baicalensis</i> Georgi	<i>S. anginosus</i>	MIC <sub>50</sub> S, 20–160 µg mL <sup>-1</sup>	30
		<i>S. gordonii</i>	MIC <sub>90</sub> S, 80–320 µg mL <sup>-1</sup>	
		<i>P. intermedia</i>		
	<i>Portulaca oleracea</i> L.	<i>E. coli</i>	313 µg mL <sup>-1</sup>	148
<i>Viola philippica</i> Cav.	Flavonoids	<i>S. aureus</i>	156 µg mL <sup>-1</sup>	
		<i>Streptococcus galactostasis</i>	39 µg mL <sup>-1</sup>	
		<i>Staphylococcus aureus</i>	78 µg mL <sup>-1</sup>	
		<i>Escherichia coli</i>	156 µg mL <sup>-1</sup>	
		<i>Streptococcus agalactiae</i>	313 µg mL <sup>-1</sup>	
		<i>Streptococcus mammariae</i>	625 µg mL <sup>-1</sup>	
		<i>Salmonella</i>	1250 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	25 µg mL <sup>-1</sup>	149
		<i>S. epidermidis</i>	25 µg mL <sup>-1</sup>	
		<i>S. epidermidis</i>	80 µg mL <sup>-1</sup>	150
		<i>S. aureus</i>	80 µg mL <sup>-1</sup>	
		<i>Shigella dysenteriae</i>	160 µg mL <sup>-1</sup>	
<i>Trollius chinensis</i> Bunge	Orientin	<i>S. pyogenes beta</i>	310 µg mL <sup>-1</sup>	
	Total flavonoids	<i>S. paratyphi A</i>	620 µg mL <sup>-1</sup>	
		<i>Enterococcus faecalis</i>	1.0 mg mL <sup>-1</sup>	151
		<i>Streptococcus mutans</i>	1.0 mg mL <sup>-1</sup>	
		<i>Candida albicans</i>	1.0 mg mL <sup>-1</sup>	
<i>Croton betaceus</i> Baill.	Hexane fraction	<i>Streptococcus mutans</i>	1.0 mg mL <sup>-1</sup>	151
<i>Croton lundianus</i> (Didr.) Müll.Arg.	Hexane fraction	<i>C. difficile</i>	8 µg mL <sup>-1</sup>	152
<i>Cullen corylifolium</i> (L.) Medik.	Phenolic extract of seeds	<i>C. difficile</i>	4 µg mL <sup>-1</sup>	
<b>Essential oils and terpenes</b>				
	Essential oil	<i>S. aureus</i>	100 µg mL <sup>-1</sup>	
		62,70,153		
	Scabertopin	<i>S. aureus</i>	80 µg mL <sup>-1</sup>	154
		<i>S. epidermidis</i>	80 µg mL <sup>-1</sup>	
		<i>Trichophyton mentagrophytes</i>	80 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	160 µg mL <sup>-1</sup>	
	Isoscabertopin			



Table 2 (Contd.)

Herbal medicine	Extract/compound	Bacteria	Antimicrobial activity (MIC)	Ref.
<i>Houttuynia cordata</i> Thunb.	Deoxyelephantopin	<i>S. epidermidi</i>	160 µg mL <sup>-1</sup>	155
		<i>Trichophyton mentagrophytes</i>	80 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	160 µg mL <sup>-1</sup>	
		<i>S. epidermidi</i>	160 µg mL <sup>-1</sup>	
		<i>Trichophyton rubrum</i>	80 µg mL <sup>-1</sup>	
	Isodeoxyelephantopin	<i>Trichophyton mentagrophytes</i>	80 µg mL <sup>-1</sup>	
		<i>Microsporum canis</i>	80 µg mL <sup>-1</sup>	
		<i>Trichophyton rubrum</i>	80 µg mL <sup>-1</sup>	
		<i>Trichophyton mentagrophytes</i>	80 µg mL <sup>-1</sup>	
		<i>Microsporum canis</i>	80 µg mL <sup>-1</sup>	
<i>Dendranthema morifolium</i> (Ramat.) Tzvelev	Essential oil	MRSA	110–1760 µg mL <sup>-1</sup>	156
		MSSA	110–1760 µg mL <sup>-1</sup>	
<i>Andrographis paniculata</i> (Burm.f.) Nees	Andrographolide	Streptococci species	200–800 µg mL <sup>-1</sup>	69
		<i>streptococci ratti</i> and obligate anaerobic bacteria such as <i>F. nucleatum</i> , <i>P. intermedia</i> , and <i>P. gingivalis</i>	100–200 µg mL <sup>-1</sup>	
		<i>E. coli</i>	50 µg mL <sup>-1</sup>	
		<i>K. pneumonia</i>	100 µg mL <sup>-1</sup>	
		<i>B. subtilis</i>	100 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	100 µg mL <sup>-1</sup>	
		<i>Mycobacterium smegmatis</i>	200 µg mL <sup>-1</sup>	
		<i>P. aeruginosa</i>	350 µg m <sup>-1</sup>	
		<i>Streptococcus thermophilus</i>	200 µg mL <sup>-1</sup>	
		<i>P. aeruginosa</i>	256 µg mL <sup>-1</sup>	
<i>Patrinia scabiosifolia</i> Link <i>Thymus mongolicus</i> (Ronniger) Ronniger	Oleanolic acid	<i>E. coli</i>	350 mL/L	87,157
	Essential oil	<i>Aspergillus niger</i>		
		<i>S. aureus</i>		
		<i>Saccharomyces cerevisiae</i>		
		<i>Aspergillus flavus</i>		
		<i>S. xylosus</i>	14.4 µL mL <sup>-1</sup>	
		<i>S. typhimurium</i>	0.009–23.48 µg mL <sup>-1</sup>	
		<i>K. pneumoniae</i>	250 ppm	
		<i>E. coli</i>	100 ppm	
		<i>S. aureus</i>		
		<i>S. aureus</i>	12 µg mL <sup>-1</sup>	
<i>Mentha suaveolens</i> ehrh. <i>Ocimum basilicum</i> L. <i>Trachyspermum ammi</i> (L.) Sprague	Essential oil	<i>Streptococcus mutans</i>	2 µg mL <sup>-1</sup>	161
	<i>Ocimum basilicum</i> L. oil	<i>Streptococcus sobrinus</i>	4 µg mL <sup>-1</sup>	
	Essential oil extracted from seeds	<i>A. tumefaciens</i>	12.5 µg mL <sup>-1</sup>	
		<i>E. coli</i>	12.5 µg mL <sup>-1</sup>	
		<i>P. lachrymans</i>	12.5 µg mL <sup>-1</sup>	
		<i>R. solanacearum</i>	12.5 µg mL <sup>-1</sup>	
		<i>X. vesicatoria</i>	6.25 µg mL <sup>-1</sup>	
		<i>B. subtilis</i>	25 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	100 µg mL <sup>-1</sup>	
		<i>S. haemolyticus</i>	50 µg mL <sup>-1</sup>	
		<i>M. oryzae</i>	6.25 µg mL <sup>-1</sup>	
<i>Allium cepa</i> L. <i>Lonicera japonica</i> Thunb.	Onion oil	<i>A. tumefaciens</i>	6.25 µg mL <sup>-1</sup>	80
	Ursolic acid	<i>E. coli</i>	25 µg mL <sup>-1</sup>	
		<i>P. lachrymans</i>	12.5 µg mL <sup>-1</sup>	
		<i>R. solanacearum</i>	12.5 µg mL <sup>-1</sup>	
		<i>X. vesicatoria</i>	12.5 µg mL <sup>-1</sup>	
		<i>B. subtilis</i>	25 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	100 µg mL <sup>-1</sup>	
		<i>S. haemolyticus</i>	50 µg mL <sup>-1</sup>	
		<i>M. oryzae</i>	6.25 µg mL <sup>-1</sup>	
		<i>A. tumefaciens</i>	6.25 µg mL <sup>-1</sup>	
<i>Salvia miltiorrhiza</i> Bunge	Cryptotanshinone	<i>E. coli</i>	25 µg mL <sup>-1</sup>	80
		<i>P. lachrymans</i>	12.5 µg mL <sup>-1</sup>	
		<i>R. solanacearum</i>	12.5 µg mL <sup>-1</sup>	
		<i>X. vesicatoria</i>	12.5 µg mL <sup>-1</sup>	
		<i>B. subtilis</i>	25 µg mL <sup>-1</sup>	
		<i>S. aureus</i>	100 µg mL <sup>-1</sup>	
		<i>S. haemolyticus</i>	50 µg mL <sup>-1</sup>	
		<i>M. oryzae</i>	6.25 µg mL <sup>-1</sup>	
		<i>A. tumefaciens</i>	6.25 µg mL <sup>-1</sup>	
	Dihydrotanshinone I	<i>E. coli</i>	25 µg mL <sup>-1</sup>	



Table 2 (Contd.)

Herbal medicine	Extract/compound	Bacteria	Antimicrobial activity (MIC)	Ref.
<i>Apium graveolens</i> L.	Sedanolid	<i>M. oryzae</i> <i>Candida parapsilasis</i> <i>C. albicans</i>	3.13 $\mu\text{g mL}^{-1}$ 100 $\mu\text{g mL}^{-1}$ 100 $\mu\text{g mL}^{-1}$	162
	Thymol	<i>E. coli</i> <i>P. aeruginosa</i> <i>Enterococcus faecalis</i> <i>Vibrio</i> <i>paraheamolyticus</i> <i>Vibrio alginolyticus</i> <i>Salmonella</i> <i>typhimurium</i>	0.04–0.64 $\mu\text{L mL}^{-1}$	67,77
<i>Taraxacum mongolicum</i> Hand.-Mazz.	Hexane extract	<i>S. aureus</i> <i>E. coli</i> <i>K. pneumoniae</i>	200 $\mu\text{g mL}^{-1}$ 400 $\mu\text{g mL}^{-1}$ 800 $\mu\text{g mL}^{-1}$	163
<i>Origanum vulgare</i> L.	Essential oils	<i>S. aureus</i> <i>Sporothrix schenckii</i> <i>Sporothrix brasiliensis</i>	0.015 $\mu\text{L mL}^{-1}$ 62–500 $\mu\text{g mL}^{-1}$ 125–250 $\mu\text{g mL}^{-1}$	164
	<i>O.vulgare</i> extracts	<i>S. aureus</i> <i>Staphylococcus epidermidis</i> <i>M. luteus</i> <i>Bacillus subtilis</i> <i>Enterococcus faecalis</i> <i>K. pneumoniae</i>	62.5–125 $\mu\text{g mL}^{-1}$	
<i>Blumea balsamifera</i> DC.	Essential oils	<i>S. aureus</i>	9.77 $\mu\text{g mL}^{-1}$	165
<i>Seriphidium herba-alba</i> (asso) Y.R.Ling	Total extract	<i>S. aureus</i> <i>B. subtilis</i> <i>E. coli</i> <i>F. solani</i> <i>C. albicans</i> <i>B. subtilis</i> <i>S. aureus</i> <i>C. albicans</i> <i>B. subtilis</i> <i>S. aureus</i>	125–500 $\mu\text{g per disc}$   62.5–500 $\mu\text{g per disc}$  25–50 $\mu\text{g per disc}$  25–50 $\mu\text{g per disc}$	166
<i>Satureja hortensis</i> L.	1,3,8-Trihydroxyeudesm-4-en-7 $\alpha$ ,11 $\beta$ H-12,6 $\alpha$ -olide	<i>B. subtilis</i> <i>S. aureus</i> <i>C. albicans</i>	25–50 $\mu\text{g per disc}$	
	Benzoic acid p-(b-D-glucopyranosyloxy)-methyl ester	<i>B. subtilis</i> <i>S. aureus</i>	25–50 $\mu\text{g per disc}$	
<i>Anethum graveolens</i> L.	Volatile oils	<i>Aerococcus viridans</i> <i>Eubacterium lentum</i> <i>Pantoea</i> spp. <i>Actinomyces naeslundii</i> <i>Staphylococcus sciuri</i> <i>Streptococcus intermedius</i>	680 $\mu\text{g mL}^{-1}$ 80 $\mu\text{g mL}^{-1}$ 170 $\mu\text{g mL}^{-1}$ 340 $\mu\text{g mL}^{-1}$ 340 $\mu\text{g mL}^{-1}$ 710 $\mu\text{g mL}^{-1}$	167
<b>Organic acids</b>				
<i>Rhus c hinensis</i> Mill.	Gallic acid	<i>P. aeruginosa</i> <i>E. coli</i> <i>S. aureus</i> <i>L. monocytogenes</i>	500 $\mu\text{g mL}^{-1}$ 1500 $\mu\text{g mL}^{-1}$ 1750 $\mu\text{g mL}^{-1}$ 2000 $\mu\text{g mL}^{-1}$	168
<b>Polysaccharides</b>				
<i>Cordyceps cicadae</i>	Polysaccharide	<i>E. coli</i>	100 $\mu\text{g mL}^{-1}$	104
<i>Polygonatum odoratum</i> (Mill.) Druce	Raw <i>P. sibiricum</i> polysaccharide	<i>E. coli</i> <i>B. subtilis</i> <i>S. aureus</i>	1230 $\mu\text{g mL}^{-1}$ 980 $\mu\text{g mL}^{-1}$ 1310 $\mu\text{g mL}^{-1}$	169
	Processing <i>P. sibiricum</i> polysaccharide	<i>E. coli</i> <i>B. subtilis</i> <i>S. aureus</i>	670 $\mu\text{g mL}^{-1}$ 1160 $\mu\text{g mL}^{-1}$ 740 $\mu\text{g mL}^{-1}$	
<b>Coumarins</b>				
<i>Cajanus cajan</i> (L.) Millsp.	Cajanuslactone	<i>S. aureus</i> ATCC 6538	31 $\mu\text{g mL}^{-1}$	170



Table 2 (Contd.)

Herbal medicine	Extract/compound	Bacteria	Antimicrobial activity (MIC)	Ref.
<b>Lignans</b>				
<i>Schisandra chinensis</i> (Turcz.) Baill.	<i>S. chinensis</i> extract	Ciprofloxacin-resistant <i>E. coli</i>	15.63 $\mu\text{g mL}^{-1}$	115
<i>Forsythia suspensa</i> (Thunb.) Vahl	Forsythin	<i>P. aeruginosa</i>	512 $\mu\text{g mL}^{-1}$	171
	Extract	<i>S. aureus</i>	MIC <sub>90</sub> , 980 $\mu\text{g mL}^{-1}$	172
		<i>S. epidermidis</i>	MIC <sub>90</sub> , 244 $\mu\text{g mL}^{-1}$	

<sup>a</sup> MIC: minimal inhibit concentration. ETEC: enterotoxigenic *Escherichia coli*. MRSA: methicillin-resistant *Staphylococcus aureus*. MSSA: methicillin sensitive *Staphylococcus aureus*.

higher than those for pure compounds and herb extracts for the most likely reason that HMF are comprised of various single herbs and the antimicrobial components only account for a relatively small percentage. Consequently, a higher concentration for HMF would be needed to ensure the active compounds have an inhibitory or bactericidal effect on pathogens. The detailed antimicrobial HMF commonly used in clinical practice are shown in Table 1.

The synergistic or additive effect of HMF and chemical antimicrobial agents has been embodied in clinical practice. For example, Pudilan oral liquid combined with azithromycin shows synergistic effects in treating paediatric pneumonia.<sup>140</sup> This compound also works in synergy with metronidazole and amoxicillin when treating *H. pylori* infection.<sup>138</sup> Combinations of Shuanghuanglian preparations and chemical antimicrobial agents (e.g., amikacin, minocycline, piperacillin/tazobactam and cefoperazone/sulbactam) exhibit synergistic or additive antimicrobial effects against extensively drug resistant *Acinetobacter baumannii*.<sup>139</sup> Combinations of Shuanghuanglian

preparations and imipenem showed synergistic effects on *Klebsiella pneumoniae*.<sup>141</sup>

### Antimicrobial activity and mechanisms of herbal components

Flavonoids are the most promising antimicrobial agents, which display favorable antibacterial activity. Most of alkaloids exhibit relatively weaker antibacterial effect, however, berberine displays strong antimicrobial activities. Many terpenes and partial essential oils display strong antimicrobial activity. Organic acids, e.g., chlorogenic acid from *Lonicera japonica* Thunb. show exploitable antimicrobial activity. According to Kuete and Efferth,<sup>142</sup> antibacterial activity parameters are given for herb extracts and pure compounds. For extracts, it is estimated that they're significantly active if their MIC values  $\leq 100 \mu\text{g mL}^{-1}$ , moderately active if  $100 < \text{MIC} \leq 625 \mu\text{g mL}^{-1}$  and weakly active if  $\text{MIC} > 625 \mu\text{g mL}^{-1}$ ; for pure compounds, they're significantly active if their MIC values  $\leq 10 \mu\text{g mL}^{-1}$ , moderately active if  $10 < \text{MIC} \leq 100 \mu\text{g mL}^{-1}$  and weakly active if  $\text{MIC} > 100 \mu\text{g mL}^{-1}$ . The antimicrobial herb extracts and their compounds described in the past two decades are summarized in Table 2.




Fig. 2 Antimicrobial mechanisms of herbal components. All, allucin; And, Andrographolide; Api, apigenin; Bai, baicalein; Ber, Berberine; Car, carvacrol; CCEO, *Cinnamomum camphora* (L.) Presl. essential oil; CCP, Cordyceps cicadae polysaccharide; Cry, Cryptotanshinone; Cur, Curcumin; DTI, dihydrotanshinone I; For, forsythin; ForB, forsythoside B; Fra, fraxetin; GA, gallic acid; Gal, Galangin; Hou, Houttuynin; IBCL, isobavachalcone; IM, imperatorin; JREO, Juniperus rigida essential oil; LA, linoleic acid; Med, (+)-medioresinol; OA, oleanolic acid; OLA, oleic acid; PF, purslane flavonoids; RH, rhein; Sch, schizandin; SFG, sophoraflavanone G; SI, Soy isoflavones; Thy, thymol; UA, ursolic acid.





The antimicrobial mechanisms of herbal components involve damage to the cell membrane and wall, inhibition of nucleic acid and protein synthesis (e.g., inhibition of DNA topoisomerase I, II and IV), inhibition of energy metabolism (e.g., inhibition of NADH-cytochrome c reductase, succinate dehydrogenase and malate dehydrogenase), inhibition of bacterial efflux pumps, and increased intracellular osmotic pressure. Organic acids also achieve their antimicrobial activities by increasing intracellular pH. In general, damage to cell membranes is the most common antimicrobial pathway. The antimicrobial mechanisms of herbal components were shown in Fig. 2.

## Conclusions and perspectives

The increasing occurrence of dangerous infections caused by resistant bacteria has made the exploration of new molecules and chemical entities an urgent topic in the medical field on a global scale. Compared to synthetic chemistry, herbs provide greater structural diversity, and offer more opportunities for identifying novel antimicrobial compounds which are the most consistently successful source of drugs. Herbs display excellent antibacterial effect due to their safety, effectiveness, antimicrobial synergism and decreased drug resistance based on their multi-component, multi-drug target.<sup>85</sup> Besides, plant secondary metabolites include heterogeneous categories of naturally existing compounds, which have been investigated since the 1850s and developed as effective drugs applied to treat diverse diseases.<sup>4,173</sup> Several studies have explored the potential of various secondary metabolites against microbial infections *in vivo* without affecting the beneficial microbes in the gastrointestinal tracts. And secondary metabolites can exert a synergistic or additive effect with less efficient antimicrobial agents combating pathogens including MDRs.<sup>174</sup> In order to find the novel antibacterial agents for combating multidrug-resistant microbes, future studies should also put an emphasis on developing the medicinal botanicals which generate a rich diversity of secondary metabolites.<sup>175</sup>

Combination of herbs and chemical antimicrobial agents for the treatment of infectious diseases is popular in clinical practice in China because of their synergistic or additive effects. Some herbal extracts or components enhanced the antibacterial activity of antimicrobial agents against sensitive and multidrug-resistant microorganisms when combined with antibiotics.<sup>176,177</sup> The synergistic or additive action was possibly related to multiple compounds in herbal extracts jointly acting on multiple sites and targets of bacteria by damaging the bacteria cell wall and membrane,<sup>178</sup> facilitating drug entry, inhibiting drug efflux pumps<sup>179</sup> and enzymes that invalidate chemical antimicrobial agents (such as penicillinase and  $\beta$ -lactamase). Meanwhile, some research technologies, such as new omics technologies and network pharmacology, become an asset for finding the most effective combinations among antimicrobial herbs or in combination with currently available synthetic antibiotics.<sup>180</sup> This provides new avenues for the prevention and treatment of infectious disease.

It should be noted that herbs exhibit different antibacterial activity due to different species, producing areas, harvest

seasons, medicinal parts, extraction, separation, and purification process. Compared to chemical antibacterial agents, herbal products show low efficiency of bacteriostasis and sterilization, poor antibacterial specificity, and incompatibility, as well as trust issues among doctors and patients. For some herbal components with antibacterial potential, their activity can be improved by structural modification.

Undoubtedly, as extensively occurring natural resources, medicinal phytochemicals play an important role in future discoveries of new drugs, but only a small percentage of them have been studied. There is still a need to screen and identify more small molecular compounds with potent bioactivity for drug discovery researchers. On top of that, one of the difficulties for future studies on numerous phytochemicals is to find more effective and appropriate forms of drug administration conducive to releasing active compounds at the target site in infectious human bodies. Another difficulty is to develop better methods used to precisely determine the botanical compounds with antimicrobial activity in plant extracts or herbal medicine formulas, which involve in complex components.

In the future, study on the antibacterial effect of herbs should also attach importance on the mechanisms of action, pharmacodynamic material basis (*i.e.*, medicinal composition), pharmacokinetics and synergistic action (e.g., herb-herb interaction, herb-chemical antibacterial agent interaction), as well as novel product development (e.g., novel drug delivery systems). The screening and purification of antimicrobial ingredients from herbs become necessary for precise pharmacodynamic evaluation and quality control. Supramolecular self-assembly and self-delivery strategy (nanoparticles and nanofibers)<sup>181</sup> can be used to construct herbal nano-antimicrobial agents for the treatment of bacterial infections. The above studies can be conducted at the molecular, subcellular, cellular tissues, organs and system level, especially utilize some modern research methods such as molecular pharmacology, cell pharmacology, network pharmacology, quantitative pharmacology, chronopharmacology, sampling techniques, *in silico* high-throughput screening (HTS), -omics technologies, synergy studies and metabonomics.<sup>175,182,183</sup>

## Author contributions

Jingru Liang: investigation, writing – original draft. Xuan Huang: investigation, writing – original draft. Guo Ma: conceptualization, writing – review & editing, project administration, funding acquisition.

## Conflicts of interest

There are no conflicts to declare.

## Abbreviations

AChE	acetylcholinesterase
ASS	acid sodium salt
CB	Cinnamon bark
CL	Curcuma longa



ETS	electron transport system
FBCI	fractional bactericidal concentration index
FICI	fractional inhibitory concentration index
FtsZ	Filamenting temperature-sensitive mutant Z
hERG	human eag-related gene
Hla	alpha-hemolysin
HMF	herbal medicine formulas
LD50	medial lethal dose
MAPK	MAP Kinase
MDR	multi-drug resistance
MFC	minimal fungicidal concentration
MIC	minimum inhibitory concentration
MOE	Magnolia officinalis extract
MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
MRSE	methicillin-resistant <i>Staphylococcus epidermidis</i>
MSSA	methicillin-sensitive <i>Staphylococcus aureus</i>
TCM	traditional Chinese medicine
WHO	World Health Organization

## Acknowledgements

Thanks for the library of Fudan University, which provides literature databases for us to complete this review. This work was supported by National Natural Science Funds of China [grant numbers 82074109, 81873078, 81374051]; Science and Research Program of Shanghai Municipal Health Commission [grant number 201740094]; Science and Research Program of Traditional Chinese Medicine of Shanghai Municipal Health Commission [grant number 2018YP001]; MHFUDU-SPFDU Joint Research Fund [grant numbers RO-MY201707, 2021MHJC11]; Key Innovative Team of Shanghai Top-Level University Capacity Building in Clinical Pharmacy and Regulatory Science at Shanghai Medical College, Fudan University [grant number HJW-R-2019-66-19].

## References

- I. Roca, M. Akova, F. Baquero, J. Carlet, M. Cavaleri, S. Coenen, J. Cohen, D. Findlay, I. Gyssens, O. E. Heuer, G. Kahlmeter, H. Kruse, R. Laxminarayan, E. Liébana, L. López-Cerero, A. MacGowan, M. Martins, J. Rodríguez-Baño, J. M. Rolain, C. Segovia, B. Sigauque, E. Tacconelli, E. Wellington and J. Vila, *New Microbes New Infect.*, 2015, **6**, 22–29.
- WHO, *Antimicrobial Resistance: Global Report on Surveillance*, 2014.
- Y. Y. Zhou, Q. Cheng, K. Liu, L. Lu and J. Zhu, *Chin. J. Antibiot.*, 2018, **43**, 5–11.
- M. G. Moloney, *Trends Pharmacol. Sci.*, 2016, **37**, 689–701.
- C. P. Commission, *Pharmacopoeia of China*, China Medical Science and Technology Press, Beijing, 2020.
- M. Tillhon, L. M. Guamán Ortiz, P. Lombardi and A. I. Scovassi, *Biochem. Pharmacol.*, 2012, **84**, 1260–1267.
- M. Wang, Z. F. Liu, H. Tang and B. A. Chen, *Chin. J. Nat. Med.*, 2018, **16**, 561–571.
- N. Sun, F. Y. Chan, Y. J. Lu, M. A. Neves, H. K. Lui, Y. Wang, K. Y. Chow, K. F. Chan, S. C. Yan, Y. C. Leung, R. Abagyan, T. H. Chan and K. Y. Wong, *PLoS One*, 2014, **9**, e97514.
- G. Pandey, S. Khatoon, M. M. Pandey and A. K. S. Rawat, *J. Ayurveda Integr. Med.*, 2018, **9**, 169–176.
- S. Bandyopadhyay, P. H. Patra, A. Mahanti, D. K. Mondal, P. Dandapat, S. Bandyopadhyay, I. Samanta, C. Lodh, A. K. Bera, D. Bhattacharyya, M. Sarkar and K. K. Baruah, *Asian Pac. J. Trop. Med.*, 2013, **6**, 315–319.
- S. Dhamgaye, F. Devaux, P. Vandeputte, N. K. Khandelwal, D. Sanglard, G. Mukhopadhyay and R. Prasad, *PLoS One*, 2014, **9**, e104554.
- H. Mahmoudvand, S. A. Ayatollahi Mousavi, A. Sepahvand, F. Shariffar, B. Ezatpour, F. Gorohi, E. Saedi Dezaki and S. Jahanbakhsh, *ISRN Pharmacol.*, 2014, **2014**, 602436.
- J. Kim, T. Ha Quang Bao, Y. K. Shin and K. Y. Kim, *World J. Microbiol. Biotechnol.*, 2018, **34**, 167.
- T. Xu, T. Kuang, H. Du, Q. Li, T. Feng, Y. Zhang and G. Fan, *Pharmacol. Res.*, 2020, **152**, 104632.
- B. L. Ma, Y. M. Ma, R. Shi, T. M. Wang, N. Zhang, C. H. Wang and Y. Yang, *J. Ethnopharmacol.*, 2010, **128**, 357–364.
- J. Wang, L. Wang, G. H. Lou, H. R. Zeng, J. Hu, Q. W. Huang, W. Peng and X. B. Yang, *Pharm. Biol.*, 2019, **57**, 193–225.
- A. Schramm, I. Baburin, S. Hering and M. Hamburger, *Planta Med.*, 2011, **77**, 692–697.
- H. A. Jung, B. S. Min, T. Yokozawa, J. H. Lee, Y. S. Kim and J. S. Choi, *Biol. Pharm. Bull.*, 2009, **32**, 1433–1438.
- H. T. Xiao, J. Peng, Y. Liang, J. Yang, X. Bai, X. Y. Hao, F. M. Yang and Q. Y. Sun, *Nat. Prod. Res.*, 2011, **25**, 1418–1422.
- C. V. Pereira, N. G. Machado and P. J. Oliveira, *Toxicol. Sci.*, 2008, **105**, 408–417.
- T. Wu, M. He, X. Zang, Y. Zhou, T. Qiu, S. Pan and X. Xu, *Biochim. Biophys. Acta*, 2013, **1828**, 2751–2756.
- S. Selvaraj, S. Krishnaswamy, V. Devashya, S. Sethuraman and U. M. Krishnan, *Prog. Lipid Res.*, 2015, **58**, 1–13.
- Z. P. Xiao, X. D. Wang, P. F. Wang, Y. Zhou, J. W. Zhang, L. Zhang, J. Zhou, S. S. Zhou, H. Ouyang, X. Y. Lin, M. Mustapa, A. Reyinbaike and H. L. Zhu, *Eur. J. Med. Chem.*, 2014, **80**, 92–100.
- N. Chinnam, P. K. Dadi, S. A. Sabri, M. Ahmad, M. A. Kabir and Z. Ahmad, *Int. J. Biol. Macromol.*, 2010, **46**, 478–486.
- D. Wu, Y. Kong, C. Han, J. Chen, L. Hu, H. Jiang and X. Shen, *Int. J. Antimicrob. Agents*, 2008, **32**, 421–426.
- L. Chen, X. Zhang, X. Peng, Y. Yang and H. Yu, *Microb. Pathog.*, 2019, **132**, 59–65.
- Y. Chen, T. Liu, K. Wang, C. Hou, S. Cai, Y. Huang, Z. Du, H. Huang, J. Kong and Y. Chen, *PLoS One*, 2016, **11**, e0153468.
- B. Y. Yun, L. Zhou, K. P. Xie, Y. J. Wang and M. J. Xie, *Yaoxue Xuebao*, 2012, **47**, 1587–1592.
- E. J. Jang, S. M. Cha, S. M. Choi and J. D. Cha, *Arch. Oral Biol.*, 2014, **59**, 1233–1241.
- S. Siri Wong, T. Pimchan and W. Naknarong, *Trop. J. Pharm. Res.*, 2015, **14**, 641–648.



- 31 W. Cai, Y. Fu, W. Zhang, X. Chen, J. Zhao, W. Song, Y. Li, Y. Huang, Z. Wu, R. Sun, C. Dong and F. Zhang, *BMC Microbiol.*, 2016, **16**, 181.
- 32 Z. L. Wang, S. Wang, Y. Kuang, Z. M. Hu, X. Qiao and M. Ye, *Pharm. Biol.*, 2018, **56**, 465–484.
- 33 B. C. Chan, M. Ip, C. B. Lau, S. L. Lui, C. Jolival, C. Ganem-Elbaz, M. Litaudon, N. E. Reiner, H. Gong, R. H. See, K. P. Fung and P. C. Leung, *J. Ethnopharmacol.*, 2011, **137**, 767–773.
- 34 J. Luo, J. L. Kong, B. Y. Dong, H. Huang, K. Wang, L. H. Wu, C. C. Hou, Y. Liang, B. Li and Y. Q. Chen, *Drug Des., Dev. Ther.*, 2016, **10**, 183–203.
- 35 S. Yang, Y. Fu, X. Wu, Z. Zhou, J. Xu, X. Zeng, N. Kuang and Y. Zeng, *Biochem. Biophys. Res. Commun.*, 2014, **451**, 36–41.
- 36 R. Dhayakaran, S. Neethirajan and X. Weng, *Biochem. Biophys. Rep.*, 2016, **6**, 149–157.
- 37 A. P. Mukne, V. Viswanathan and A. G. Phadatare, *Pharmacogn. Rev.*, 2011, **5**, 13–18.
- 38 R. P. N. Albert Dhayakaran, J. S. Xue and J. Shi, *LWT-Food Sci. Technol.*, 2015, **63**, 859–865.
- 39 Q. Wang, H. Wang and M. Xie, *Arch. Microbiol.*, 2010, **192**, 893–898.
- 40 J. D. Cha, S. E. Moon, J. Y. Kim, E. K. Jung and Y. S. Lee, *Phytother. Res.*, 2009, **23**, 1326–1331.
- 41 H. Tsuchiya and M. Iinuma, *Phytomedicine*, 2000, **7**, 161–165.
- 42 S. H. Mun, O. H. Kang, D. K. Joung, S. B. Kim, Y. S. Seo, J. G. Choi, Y. S. Lee, S. W. Cha, Y. S. Ahn, S. H. Han and D. Y. Kwon, *Evidence-Based Complementary Altern. Med.*, 2013, **2013**, 823794.
- 43 T. P. Cushnie and A. J. Lamb, *Phytomedicine*, 2006, **13**, 187–191.
- 44 J. Ouyang, F. Sun, W. Feng, Y. Xie, L. Ren and Y. Chen, *Chemotherapy*, 2018, **63**, 20–28.
- 45 G. Eumkeb, S. Sakdarat and S. Siri Wong, *Phytomedicine*, 2010, **18**, 40–45.
- 46 M. Karaman, F. Firinci, Z. Arkan Ayyildiz and I. H. Bahar, *Mikrobiyol. Bul.*, 2013, **47**, 192–194.
- 47 D. Praditya, L. Kirchhoff, J. Brünig, H. Rachmawati, J. Steinmann and E. Steinmann, *Front. Microbiol.*, 2019, **10**, 912.
- 48 C. Dai, Y. Wang, G. Sharma, J. Shen, T. Velkov and X. Xiao, *Antioxid.*, 2020, **9**, 506.
- 49 Y. Y. Yi, J. J. He, J. Q. Su, S. Z. Kong, J. Y. Su, Y. C. Li, S. H. Huang, C. W. Li, X. P. Lai and Z. R. Su, *Fitoterapia*, 2013, **84**, 135–139.
- 50 Y. C. Li, H. C. Liang, H. M. Chen, L. R. Tan, Y. Y. Yi, Z. Qin, W. M. Zhang, D. W. Wu, C. W. Li, R. F. Lin, Z. R. Su and X. P. Lai, *Phytomedicine*, 2012, **20**, 77–83.
- 51 Z. W. Tang, C. Peng, M. Dai and B. Han, *Fitoterapia*, 2015, **106**, 41–45.
- 52 S. Tariq, S. Wani, W. Rasool, K. Shafi, M. A. Bhat, A. Prabhakar, A. H. Shalla and M. A. Rather, *Microb. Pathog.*, 2019, **134**, 103580.
- 53 A. Brochot, A. Guilbot, L. Haddioui and C. Roques, *Microbiologyopen*, 2017, **6**, e00459.
- 54 H. Lu, X. Wu, Y. Liang and J. Zhang, *Chem. Pharm. Bull.*, 2006, **54**, 936–940.
- 55 G. S. Kim, D. H. Kim, J. J. Lim, J. J. Lee, D. Y. Han, W. M. Lee, W. C. Jung, W. G. Min, C. G. Won, M. H. Rhee, H. J. Lee and S. Kim, *Biol. Pharm. Bull.*, 2008, **31**, 2012–2017.
- 56 T. Wang, W. Huang, Q. Duan, J. Wang, H. Cheng, J. Shao, F. Li and D. Wu, *Mol. Biol. Rep.*, 2019, **46**, 471–477.
- 57 Y. L. Ma, Z. F. Han, J. R. Wang, L. M. Zhang, L. J. Qin, Y. Wang and C. X. Yang, *Zhongcaoyao*, 2001, **32**, 334–337.
- 58 G. Haiyan, H. Lijuan, L. Shaoyu, Z. Chen and M. A. Ashraf, *Saudi J. Biol. Sci.*, 2016, **23**, 524–530.
- 59 P. S. Yap, S. H. Lim, C. P. Hu and B. C. Yiap, *Phytomedicine*, 2013, **20**, 710–713.
- 60 R. Naveed, I. Hussain, A. Tawab, M. Tariq, M. Rahman, S. Hameed, M. S. Mahmood, A. B. Siddique and M. Iqbal, *BMC Complementary Altern. Med.*, 2013, **13**, 265.
- 61 N. G. Vasconcelos, J. Croda and S. Simionatto, *Microb. Pathog.*, 2018, **120**, 198–203.
- 62 S. M. Razavi Rohani, M. Moradi, T. Mehdizadeh, S. S. Saei-Dehkordi and M. W. Griffiths, *LWT-Food Sci. Technol.*, 2011, **44**, 2260–2265.
- 63 P. Putnik, D. Gabrić, S. Roohinejad, F. J. Barba, D. Granato, K. Mallikarjunan, J. M. Lorenzo and D. Bursac Kovačević, *Food Chem.*, 2019, **276**, 680–691.
- 64 S. Ankri and D. Mirelman, *Microbes Infect.*, 1999, **1**, 125–129.
- 65 Y. Yamada and K. Azuma, *Antimicrob. Agents Chemother.*, 1977, **11**, 743–749.
- 66 J. Han, L. Lawson, G. Han and P. Han, *Anal. Biochem.*, 1995, **225**, 157–160.
- 67 A. Marchese, R. Barbieri, A. Sanches-Silva, M. Daglia, S. F. Nabavi, N. J. Jafari and S. M. Nabavi, *Trends Food Sci. Technol.*, 2016, **52**, 49–56.
- 68 Z. J. Shao, X. W. Zheng, T. Feng, J. Huang, J. Chen, Y. Y. Wu, L. M. Zhou, W. W. Tu and H. Li, *Can. J. Physiol. Pharmacol.*, 2012, **90**, 647–653.
- 69 M. Arifullah, N. D. Namsa, M. Mandal, K. K. Chiruvella, P. Vikrama and G. R. Gopal, *Asian Pac. J. Trop. Biomed.*, 2013, **3**, 604–610.
- 70 C. M. Wu, J. L. Cao, M. H. Zheng, Y. Ou, L. Zhang, X. Q. Zhu and J. X. Song, *J. Int. Med. Res.*, 2008, **36**, 178–186.
- 71 D. M. Liu, J. C. Bi, H. Q. Qie, P. Jiao and P. L. Yan, *J. Tradit. Chin. Med.*, 2008, **6**, 654–655.
- 72 J. A. Jesus, J. H. Lago, M. D. Laurenti, E. S. Yamamoto and L. F. Passero, *Evidence-Based Complementary Altern. Med.*, 2015, **2015**, 620472.
- 73 A. M. Grudniak, A. Kurek, J. Szarlak and K. I. Wolska, *Curr. Microbiol.*, 2011, **62**, 1331–1336.
- 74 A. Kurek, A. M. Grudniak, M. Szwed, A. Klicka, L. Samluk, K. I. Wolska, W. Janiszowska and M. Popowska, *Antonie van Leeuwenhoek*, 2010, **97**, 61–68.
- 75 G. S. Li, W. Zhang, T. Peng and M. J. Guo, *Mod. Tradit. Chin. Med. Mater. Med. World Sci. Technol.*, 2014, **16**, 610–613.
- 76 S. Xu, D. Li, L. Pei, H. Yao, C. Wang, H. Cai, H. Yao, X. Wu and J. Xu, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 2811–2814.



- 77 H. Miladi, T. Zmantar, Y. Chaabouni, K. Fedhila, A. Bakhrouf, K. Mahdouani and K. Chaieb, *Microb. Pathog.*, 2016, **99**, 95–100.
- 78 H. Miladi, T. Zmantar, B. Kouidhi, Y. M. A. Al Qurashi, A. Bakhrouf, Y. Chaabouni, K. Mahdouani and K. Chaieb, *Microb. Pathog.*, 2017, **112**, 156–163.
- 79 D. S. Lee, S. H. Lee, J. G. Noh and S. D. Hong, *Biosci., Biotechnol., Biochem.*, 1999, **63**, 2236–2239.
- 80 J. Zhao, J. Lou, Y. Mou, P. Li, J. Wu and L. Zhou, *Molecules*, 2011, **16**, 2259–2267.
- 81 W. Chen and Q. Z. Liu, *Chin. J. Drug. Appl. Monit.*, 2007, **6**, 38–39.
- 82 B. Marongiu, A. Piras, S. Porcedda, D. Falconieri, A. Maxia, M. A. Frau, M. J. Gonçalves, C. Cavaleiro and L. Salgueiro, *Nat. Prod. Res.*, 2013, **27**, 1521–1527.
- 83 K. Akilandeswari and K. Ruckmani, *Cell. Mol. Biol.*, 2016, **62**, 74–82.
- 84 Y. Morimoto, T. Baba, T. Sasaki and K. Hiramatsu, *Int. J. Antimicrob. Agents*, 2015, **46**, 666–673.
- 85 S. C. Ricke, *Poult. Sci.*, 2003, **82**, 632–639.
- 86 F. Van Immerseel, J. B. Russell, M. D. Flythe, I. Gantois, L. Timbermont, F. Pasmans, F. Haesebrouck and R. Ducatelle, *Avian Pathol.*, 2006, **35**, 182–188.
- 87 J. Zhang, Z. G. Tian, J. H. Wang and A. R. Wang, *Chin. J. Prev. Vet. Med.*, 2011, **3**, 323–328.
- 88 J. Xiong, S. Li, W. Wang, Y. Hong, K. Tang and Q. Luo, *Food Chem.*, 2013, **138**, 327–333.
- 89 G. Li, X. Wang, Y. Xu, B. Zhang and X. Xia, *Eur. Food Res. Technol.*, 2014, **238**, 589–596.
- 90 S. N. Park, Y. K. Lim, M. H. Choi, E. Cho, I. S. Bang, J. M. Kim, S. J. Ahn and J. K. Kook, *Curr. Microbiol.*, 2018, **75**, 11–19.
- 91 M. J. Kim, C. Kim, J. Y. Park, Y. Lim, S. N. Park, S. Ahn and J. K. Kook, *Int. J. Oral Sci.*, 2011, **36**, 7–11.
- 92 C. M. Wang, Y. L. Jhan, S. J. Tsai and C. H. Chou, *Molecules*, 2016, **21**.
- 93 S. Schmidt, K. Heymann, M. F. Melzig, S. Bereswill and M. M. Heimesaat, *Planta Med.*, 2016, **82**, 1540–1545.
- 94 D. R. Long, J. Mead, J. M. Hendricks, M. E. Hardy and J. M. Voyich, *Antimicrob. Agents Chemother.*, 2013, **57**, 241–247.
- 95 Y. Y. Lim and E. P. L. Quah, *Food Chem.*, 2007, **103**, 734–740.
- 96 B. C. Chan, X. Q. Han, S. L. Lui, C. W. Wong, T. B. Wang, D. W. Cheung, S. W. Cheng, M. Ip, S. Q. Han, X. S. Yang, C. Jolival, C. B. Lau, P. C. Leung and K. P. Fung, *J. Pharm. Pharmacol.*, 2015, **67**, 107–116.
- 97 K. P. Fung, Q. B. Han, M. Ip, X. S. Yang, C. B. Lau and B. C. Chan, *Hong Kong Med. J.*, 2017, **23**(Suppl 5), 38–42.
- 98 M. G. Aly and N. M. Afr, *J. Biotechnol.*, 2011, **10**, 12058–12063.
- 99 J. Wang, H. Zhao, W. Kong, C. Jin, Y. Zhao, Y. Qu and X. Xiao, *Phytomedicine*, 2010, **17**, 684–689.
- 100 J. Azelmat, J. F. Larente and D. Grenier, *Arch. Oral Biol.*, 2015, **60**, 342–346.
- 101 Y. Y. Hou, Master thesis, Shanghai Ocean University, 2015.
- 102 Y. Wu, X. Wang, B. Shen, L. Kang and E. Fan, *Recent Pat. Food, Nutr. Agric.*, 2013, **5**, 57–61.
- 103 S. K. Sharma, N. Gautam and N. S. Atri, *BMC Complementary Altern. Med.*, 2015, **15**, 446.
- 104 Y. Zhang, Y. T. Wu, W. Zheng, X. X. Han, Y. H. Jiang, P. L. Hu and L. E. Shi, *J. Funct. Foods*, 2017, **38**, 273–279.
- 105 G. Y. Zuo, G. C. Wang, Y. B. Zhao, G. L. Xu, X. Y. Hao, J. Han and Q. Zhao, *J. Ethnopharmacol.*, 2008, **120**, 287–290.
- 106 T. T. Zhang, J. H. Pan, L. W. Nie, B. J. Wu, S. S. Zhao and Y. Yang, *J. Biol.*, 2005, **22**, 41–42.
- 107 S. Lee, D. S. Shin, J. S. Kim, K. B. Oh and S. S. Kang, *Arch. Pharmacol. Res.*, 2003, **26**, 449–452.
- 108 Q. Xie, *Rec. Nat. Prod.*, 2015, **10**, 294–306.
- 109 P. Ouyang, J. Chen, M. Sun, Z. Yin, J. Lin, H. Fu, G. Shu, C. He, C. Lv, X. Deng, K. Wang, Y. Geng and L. Yin, *Antonie van Leeuwenhoek*, 2016, **109**, 915–922.
- 110 L. M. Liu, R. H. Wang, L. Chen, Q. Yang, X. G. Weng and J. H. Sun, *J. Tradit. Chin. Med.*, 2009, **16**, 39–42.
- 111 S. H. Duncan, H. J. Flint and C. S. Stewart, *FEMS Microbiol. Lett.*, 1998, **164**, 283–288.
- 112 S. Liu, K. P. Xie, D. Zou, L. Zhou and M. J. Xie, *Chin. J. Microecol.*, 2014, **26**, 1123–1126.
- 113 H. Wang, D. Zou, K. Xie and M. Xie, *Mol. Med. Rep.*, 2014, **10**, 2341–2345.
- 114 M. Saleem, H. J. Kim, M. S. Ali and Y. S. Lee, *Nat. Prod. Rep.*, 2005, **22**, 696–716.
- 115 S. Y. Yan, S. Q. Lin, J. Fu, G. M. Li, D. J. Wang and R. Z. Wan, *Chin. J. Exp. Tradit. Med. Formul.*, 2014, **20**, 142–146.
- 116 Y. J. Feng, Y. Y. Zhang, R. X. Wang and S. G. Li, *Food. Ferment. Ind.*, 2016, **42**, 72–76.
- 117 H. Choi, J. Lee, Y. S. Chang, E. R. Woo and D. G. Lee, *Biochim. Biophys. Acta*, 2013, **1828**, 2002–2006.
- 118 B. Hwang, J. Lee, Q. H. Liu, E. R. Woo and D. G. Lee, *Molecules*, 2010, **15**, 3507–3516.
- 119 K. C. Chiu, Y. H. Shih, T. H. Wang, W. C. Lan, P. J. Li, H. S. Jhuang, S. M. Hsia, Y. W. Shen, M. Yuan-Chien Chen and T. M. Shieh, *J. Formosan Med. Assoc.*, 2021, **120**, 827–837.
- 120 Y. J. Hu, J. L. Qiao, X. Zhang and C. R. Ge, *J. Food Biochem.*, 2011, **35**, 425–441.
- 121 B. Chang, Y. Lee, Y. Ku, K. Bae and C. Chung, *Planta Med.*, 1998, **64**, 367–369.
- 122 J. Feng, J. Y. Li and X. D. Zhou, *Sichuan Daxue Xuebao, Yixueban*, 2007, **38**, 456–458.
- 123 Y. Hu, J. Qiao, X. Zhang and C. Ge, *J. Sci. Food Agric.*, 2011, **91**, 1050–1056.
- 124 C. S. Zuo, *Chin. J. Vet. Med.*, 2015, **51**, 54–56.
- 125 S. M. Zheng, J. J. Huang, W. U. Qing and S. Sha, *Acta Hydrobiol. Sin.*, 2010, **34**, 57–64.
- 126 X. Wang, Y. Z. Cui and T. S. Han, *China J. Tradit. Chin. Med. Pharm.*, 2009, **37**, 169–171.
- 127 D. L. Zhang, D. F. Tang, Q. Zheng, M. Yang, D. Liu and Y. Tang, *Zhongcaoyao*, 2015, **46**, 3771–3778.
- 128 Y. Chen, L. J. Hu and T. T. Wang, *World Chin. Med.*, 2018, **10**, 2449–2452.
- 129 X. U. Peng, *China Mod. Med.*, 2018, **33**, 65–67.
- 130 P. Xu, *China Mod. Med.*, 2013, **9**, 84–85.
- 131 D. M. Ma, Q. C. Tao and H. W. Qi, *Lab. Med.*, 2018, **9**, 1091–1094.





- 132 X. Y. Liang, H. Y. Zhu, X. M. Liu and M. Pan, *Lab. Med.*, 2015, **3**, 261–264.
- 133 J. Feng, Y. H. Wei, S. X. Zhou, L. L. Jiang and L. Wang, *Chinese J. Vet. Drug*, 2017, **51**, 30–35.
- 134 Y. F. Luan, X. S. Kong, J. Wang and Y. Q. Zhang, *J. Tradit. Chin. Med.*, 2011, **11**, 810–812.
- 135 X. Y. Zhu, C. Peng and M. Dai, *J. Sichuan Tradit. Chin. Med.*, 2014, **4**, 62–65.
- 136 C. J. Yuan, F. G. Lu and Y. W. Zhu, *J. Tradit. Chin. Med.*, 2005, **10**, 60–61.
- 137 X. Chen, L. Hu, H. Wu, W. Liu, S. Chen, A. Zhou and Y. Liu, *Evidence-Based Complementary Altern. Med.*, 2018, **2018**, 6810369.
- 138 X. Y. Zhi, E. H. Cui, Y. P. Fan, W. R. Ma, Y. Y. Xu, L. Z. X. Suo and X. P. Song, *Xibei Nongye Xuebao*, 2014, **23**, 114–119.
- 139 X. Wang, Y. Z. Cui, H. Shao and T. S. Han, *J. Northeast Agric.*, 2011, **42**, 115–118.
- 140 L. J. Hu, W. Liu, H. H. Wu, L. Li and A. J. Zhou, *Mod. Chin. Med.*, 2016, **18**, 307–311.
- 141 D. M. Ma, Q. C. Tao, D. K. Jiang and Y. Y. Zhang, *Internet J. Lab. Med.*, 2020, **9**, 1052–1055+1059.
- 142 V. Kuete and T. Efferth, *Front. Pharmacol.*, 2010, **1**, 123.
- 143 Y. Liu, Y. Zhao, D. L. Guo, W. W. Liu and Y. X. Liu, *Chin. Herb. Med.*, 2017, **9**, 353–357.
- 144 N. Küükboyacı, S. Zkan, N. Adigüzel and F. Tosun, *Turk. J. Biol.*, 2011, **35**, 379–385.
- 145 B. A. Bhat, W. R. Mir, B. A. Sheikh, M. A. Rather, T. U. H. Dar and M. A. Mir, *J. Ethnopharmacol.*, 2022, **291**, 115046.
- 146 R. De, P. Kundu, S. Swarnakar, T. Ramamurthy, A. Chowdhury, G. B. Nair and A. K. Mukhopadhyay, *Antimicrob. Agents Chemother.*, 2009, **53**, 1592–1597.
- 147 N. Niamsa and C. Sittiwet, *J. Toxicol. Pharmacol.*, 2009, **4**, 173–177.
- 148 G. N. Chen, F. L. Sun, Y. R. Yan and M. M. Liu, *ChemBioEng.*, 2015, **32**, 34–37.
- 149 M. Miski, A. Ulubelen, C. Johansson and T. J. Mabry, *J. Nat. Prod.*, 1983, **46**, 874–875.
- 150 P. Liu, G. H. Chen, S. H. Deng, Y. L. Liu and J. M. Tong, *Chin. J. Exp. Tradit. Med. Formul.*, 2013, **19**, 207–210.
- 151 R. F. H. André, P. G. S. Erasmo, L. Francisca, S. G. C. Anabela, R. Alyne and C. L. Eliana, *LWT–Food Sci. Technol.*, 2021, **139**, 110521.
- 152 X. W. Liu, Y. J. Yang, Z. Qin, S. H. Li, L. X. Bai, W. B. Ge and J. Y. Li, *Front. Pharmacol.*, 2022, **13**, 914188.
- 153 N. Benkeblia, *LWT–Food Sci. Technol.*, 2004, **37**, 263–268.
- 154 S. Y. Liu, M. X. Zhang, Y. H. Wu and X. H. Yang, *J. Northeast Norm. Univ.*, 2011, **43**, 93–96.
- 155 Y. Sekita, K. Murakami, H. Yumoto, H. Mizuguchi, T. Amoh, S. Ogino, T. Matsuo, Y. Miyake, H. Fukui and Y. Kashiwada, *Biosci., Biotechnol., Biochem.*, 2016, **80**, 1205–1213.
- 156 J. Eun-Kyung, *J. Bacteriol. Virol.*, 2009, **39**, 61–69.
- 157 M. Omidbeygi, M. Barzegar, Z. Hamidi and H. Naghdibadi, *Food Control*, 2007, **18**, 1518–1523.
- 158 G. L. Petretto, F. Fancello, S. Zara, M. Foddai, N. P. Mangia, M. L. Sanna, E. A. Omer, L. Menghini, M. Chessa and G. Pintore, *J. Food Sci.*, 2014, **79**, M369–M377.
- 159 D. Beatovic, D. Krstic-Milosevic and S. Trifunovic, *Rec. Nat. Prod.*, 2015, **9**, 62–75.
- 160 M. Hassanshahian, Z. Bayat, S. Saeidi and Y. Shiri, *Int. J. Biomed. Adv. Res.*, 2014, **2**, 18–24.
- 161 A. M. Mahmoud, R. M. A. El-Baky, A. B. F. Ahmed and G. F. M. Gad, *Am. J. Microbiol. Res.*, 2016, **4**, 16–25.
- 162 R. A. Momin and M. G. Nair, *J. Agric. Food Chem.*, 2001, **49**, 142–145.
- 163 K. Díaz, L. Espinoza, A. Madrid, L. Pizarro and R. Chamy, *Evidence-Based Complementary Altern. Med.*, 2018, **2018**, 2706417.
- 164 S. Soltani, A. Shakeri, M. Iranshahi and M. Boozari, *Iran. J. Pharm. Res.*, 2021, **20**, 268–285.
- 165 H. Yang, Y. Gao, L. Long, Y. Cai, J. Liao, J. Peng and L. Wang, *Arch. Microbiol.*, 2021, **203**, 3981–3988.
- 166 T. A. Mohamed, A. A. Abd El Aty, A. A. Shahat, N. S. Abdel-Azim, K. A. Shams, A. A. Elshamy, M. M. Ahmed, S. H. H. Youns, T. M. El-Wassimy, S. A. El-Toumy and M. F. Hegazy, *Nat. Prod. Res.*, 2021, **35**, 1959–1967.
- 167 M. Popa, L. Mărutescu, E. Oprea, C. Bleotu, C. Kamezan, M. C. Chifiriuc and G. Grădistanu Pircalabioru, *Antibiot.*, 2020, **9**, 428.
- 168 A. Borges, C. Ferreira, M. J. Saavedra and M. Simões, *Microb. Drug Resist.*, 2013, **19**, 256–265.
- 169 G. H. Cao, Z. D. Li, R. H. Zhao, Q. R. Zhang, J. B. Li, Z. W. He, K. Kang and S. He, *Food. Sci. Technol.*, 2017, **42**, 202–206.
- 170 Y. Kong, Y. J. Fu, Y. G. Zu, F. R. Chang, Y. H. Chen, X. L. Liu and H. M. Schiebel, *Food Chem.*, 2010, **121**, 1150–1155.
- 171 Y. M. Wang and H. J. Cheng, *Mod. Chin. Med.*, 2013, **15**, 950–953.
- 172 Z. X. Li, X. H. Wang, J. H. Zhao, J. F. Yang and X. Wang, *J. Tradit. Chin. Med.*, 2007, **24**, 328–331.
- 173 J. N. Kabera, E. Semana, A. R. Mussa and X. He, *J. Pharm. Pharmacol.*, 2014, **2**, 377–392.
- 174 K. S. Allemailem, *J. Pharm. BioAllied Sci.*, 2021, **13**, 155–162.
- 175 U. Anand, N. Jacobo-Herrera, A. Altemimi and N. Lakhssassi, *Metabolites*, 2019, **9**, 258.
- 176 M. F. Haroun and R. S. Al-Kayali, *Iran. J. Basic Med. Sci.*, 2016, **19**, 1193–1200.
- 177 M. Park, L. Horn, V. Lappi, D. Boxrud, C. Hedberg and B. Jeon, *Pathogens*, 2022, **11**.
- 178 S. Hossain, M. Yousaf, Y. Liu, D. Chang and X. Zhou, *Front. Pharmacol.*, 2022, **13**, 876183.
- 179 J. E. Lan, X. J. Li, X. F. Zhu, Z. L. Sun, J. M. He, M. Zloh, S. Gibbons and Q. Mu, *Nat. Prod. Res.*, 2021, **35**, 1881–1886.
- 180 F. J. Álvarez-Martínez, E. Barrajón-Catalán, M. Herranz-López and V. Micol, *Phytomedicine*, 2021, **90**, 153626.
- 181 T. Li, P. Wang, W. Guo, X. Huang, X. Tian, G. Wu, B. Xu, F. Li, C. Yan, X. J. Liang and H. Lei, *ACS Nano*, 2019, **13**, 6770–6781.
- 182 M. O. Osungunna, *J. Microbiol., Biotechnol. Food Sci.*, 2020, **9**, 727–735.
- 183 F. J. Álvarez-Martínez, E. Barrajón-Catalán and V. Micol, *Biomedicines*, 2020, **8**, 405.

